

INDEX

- Abbott Laboratories, 3, 5–6, 13–15, 233
- Ab initio:
- calculations, 20–21, 23
 - fold prediction, 247
 - geometry optimization, 51
 - implications of, 271
 - quantum mechanics, 50
- Abnormalities, hereditary, 40
- Absorption:
- ADMET, *see* Absorption, distribution, metabolism, elimination, and toxicity (ADMET) studies
 - antimigraine drugs, 202
 - bisphosphonates, 207
 - enhancement strategies, 124–126
 - significance of, 108–109, 111
- Absorption, distribution, metabolism, elimination, and toxicity (ADMET) studies:
- absorption assurance, 57–58
 - biomedical polymers, 384
 - characterized, 110, 136, 214, 235
 - defined, 2
 - directing distribution, 58–59
 - drug discovery and development process, 18, 27, 33, 61, 79–81
 - drug handling profiles, 41
 - efficacy, 73–74, 84
 - elimination, optimization of, 65
 - future directions for, 79
 - handle, 176
 - herbal remedies, 59–62
 - HTS systems, 33, 35–37
 - metabolism controls, 63–65
 - molecular conformation, 55
 - parameter pharmacophores, 74
 - profiling, 18, 39, 41, 69–70, 84
 - proteomics, 259
 - SARs, 49, 67–70, 80
 - structural motifs/patterns, 39, 67, 79, 84
 - synergy, 61–62, 79
 - toxicity, avoidance strategies, 65–67, 262
- Absorption high-throughput screening (AHTS) systems, 57–58
- Academic laboratories, 133
- Accelerator mass spectrometry, 374
- Accelrys, Ltd., 276
- Acceptors, H-bond, 140
- Accessibility, significance of, 109
- Accession number, 254
- ACE (α -chloroethyloxycarbonyl), 325
- Acetophenones, 176
- Acetylation, 5, 275
- Acetylcholine, 296–297, 313
- Acetylcholinesterase (AChE):
- inhibitors, 224–225
 - defined, 371
- Acetylenes, 189
- Achyranthes bidentata*, 408

- Acid(s), 3, 111, 185. *See also specific types of acids*
 Acid-base, implications of, 134, 385
 Acquired immunodeficiency syndrome (AIDS), 29
 Acrolein, 412
 Acromegaly, 181
 Acronyms, 19, 22
 ACS Software, 48, 281
 Actimmune, 30
 Activase, 29
 Active pharmaceutical ingredient (API), 359
 Active site docking, 57
 Active transport, 111–112, 139, 394
 Activity-based probes, 261
 Acute inflammatory process, 407
 Acute peptic ulcer, 296
 Acute toxicity, 107, 109, 413
 Acylation/acylating agents, 152, 175
 Acyl groups, 172, 415
 Acylguanidines, 179
 Adaptogens:
 botanicals, 407–408
 defined, 407
 Rasayana botanicals, 408–409
 Adenine, 105
 Adenosine, 172
 Adenovirus, 372
 ADEPT, 146
 A/DHTS, 58
 Adipose tissue, 58
 Adjustive medicine, 407–409
 ADME, *see* Absorption, distribution, metabolism, and excretion (ADME)
 Administrative costs, 3
 Adoptive immunotherapy, 370, 372–373
 Adrenaline, 218, 296
 Advanced Chem Tech, 24
 Adverse effects, *see specific drugs*
 Afferent, 146
 Affinity, 76, 150
 Agendia, 263
 Agglomerative hierarchical clustering method, 139
 Aggressiveness, 370
 Agranulocytosis, 220
 AIDD, 146
 Airway inflammatory diseases, 314
 Alacepril, 127
 Alanine, 124, 127
 Alanine aminotransferase, 415
 Albumen, 114
 Alchemy III, 48, 281
 Alcohol(s), 177, 186–187, 189, 191, 348–349
 Alcoholysis, 189
 Aldehyde dehydrogenase inhibitors, 413
 Aldehydes, 178, 188, 275
 Aldose reductase inhibitor, 183
 Aldosterone, 119, 372
 Alendronate sodium, 208–209
 Alfentanil, 341, 343
 Alferon N, 30
 Aliphatic morpholine, 225
 Alkaline phosphatase, 132, 369, 412, 419
 Alkaloids, 223, 415, 418
 Alkylating agents, 411
 Alkylation, 178, 180
 Alkylators, 413
 Alkyl bromide, 178, 186
 Alkyl groups, 357
 Alkylguanine-DNA alkyltransferase (AGT), 370
 Alkyl hydrazines, 191
 Alkyl nitriles, 187
 Allergies/allergic reaction, 111
 Allograft rejection, 181
 Allosteric protein, 246
 Allyl amine polymers, 394
 17-Allylaminogeldanamycin, 373
 α -Azidoalcohols, 187
 α -Bromoketones, 187
 α -haloketone, 107
 α -Ketothiazole, 186
 Altana Pharma, 233
 Aluminum salts, 386
 Alveolar macrophages, 409
 Alzheimer's disease, 10, 31, 369–369, 152, 371
 AMBER parameters, 20, 50, 282
 American Chemistry Council Long-Range Research Initiative, 66
 American Heart Association (AHA), 315
 American Hospital Supply, 208
 Amersham, 242
 Amgen, 29–30
 Amide nitrogen, 357
 Amidines, 301–303
 Amidinium cation, 302
 Amifostine, 412–413
 Amikacim-resistant *Klebsiella pneumoniae*, 400
 Amine(s):
 acylation of, 141
 characterized, 151–152, 189
 end-product, 71
 parallel solution-phase synthesis, 170, 178, 184
 polymers, 387–388
 quaternary, 388
 secondary, 185–186, 188
 synthesis of, 191
 tags, 133
 tertiary, 111, 185
 Amino acids, 31, 117–118, 123, 125, 132–133, 151, 242, 247, 318, 361, 398
 Amino alcohols, 177
 Aminobenzamides, 174
 4-Amino-1-benzylpiperidines, 176
 Aminobenzamides, 174
 Amino groups, 125
 Aminomethyl styrene, 134

- Aminopyridazine, 224
- 5-Aminotetrazole, 172
- Aminothiols, 412
- Amiodarone, 221
- Amlodipine, 207
- Ammonia, 178
- Ammonium groups, 387, 390, 400
- Ammonium salts, 344, 394
- Amnesia, 340
- Amnestics, 340
- 5'-AMP, 77
- AMPA, 183
- Anaferine, 415
- Analgesics:
 - characterized, 339–340
 - remifentanil, 340–350
 - ultrashort, 339–350
- Analog(s):
 - attrition, 108
 - defined, 199
 - design of, *see* Analog design
 - direct, 214
 - drug, 202–208
 - early phase, 199–202
 - production, 104, 107
 - research studies, 199–209
- Analog design:
 - emergence of new activities, 216–217
 - natural compound models, 216
 - pharmacophore-based, 215
 - terminology, 214–215
- Analoging, *see* Analog(s)
- pit viper venom illustration, 120
- significance of, 116
- Analytical chemistry:
 - characterized, 18–19, 27
 - examples of, 75–78
 - trends in, 74–75
- Andrade-Gordon, Patricia, Dr., 315
- Anemia, 29, 408
- Anesthesia, 339–340. *See also* Remifentanil
- Angicoagulants, 226
- Angina/angina pectoralis, 116, 207, 217, 221
- Angioplasty, 30
- Angiotensin-converting enzyme (ACE):
 - characterized, 117–118, 120
 - inhibitors, 119, 121–123, 126, 199–200, 214, 222
 - peptide bond hydrolysis, 120
- Angiotensin II receptors:
 - antagonist losartan, 215–216
 - characterized, 117–119, 128, 183
- Anhydride, 185, 349
- Anhydroerythromycin, 3, 6
- 4-Anilidopiperidine acid, 348
- Aniline groups, 107, 178
- Animal models/studies:
 - amistofine, 413
 - analgesic opiates, 342–344
 - antiulcer drugs, 298–300, 305
 - benefits of, 222, 234, 261–262
 - clarithromycin, 6
 - Clostridium difficile* toxins, 400
 - discovery route, 104
 - drug-target interaction, 372
 - erythromycin, 6–7
 - insulin-resistant, 200
 - in vivo diuretic effects, 324
 - nuclear imaging, 370
 - parallel solution-phase synthesis, 170
 - vasopressin receptor agonists, 316–319, 321, 327, 330–332
- Anion-exchange resins, 398
- Anionic polymers, 398–399
- Annexin V, 376
- Anorexia, HIV-related, 220
- Anthracyclines, 414
- Anthrax toxin, 397
- 9-Anthrilmethyl ester, 186
- Antiadrenergic drugs, 300
- Antiallergic agents, 172
- Antiarrhythmics, 342
- Antibacterial agents, 223, 310, 400
- Antibiotics:
 - antitumor, 180
 - azithromycin, 6, 9–12
 - characterized, 226, 375, 399
 - clarithromycin, 6–8, 10, 12
 - erythromycin, 3–8, 10, 12, 182, 226
 - resistance to, 112
 - tetracycline, 228
 - treatment, 397–398, 401
 - ulcer treatment, 310
- Antibodies, 253, 368
- Antibody/epitope, posttranslational modifications, 244–245
- Anticancer agents:
 - camptothecin (CPT), 43–44, 59
 - characterized, 13
 - diadzein, 46
 - genistein, 46
 - methotrexate, 105–106, 116, 410
 - multidrug resistance (MDR), 42–45, 59
 - paclitaxel (PAC), 42–43, 52, 59, 68–69, 82–83, 414
 - phytoalexins, 45–46
 - research study, ADMET SAR, 68
 - resistance to, 112
 - topotecan, 43–44
- Anticholinergic drugs, 297, 300
- Anticonvulsants, 314
- Antidepressants, 14, 224
- Antidiuresis, 316
- Antidopaminergic properties, 203

- Antiemetic agents, 203
- Antifungal:
 - assays, 175
 - therapy, 206
- Antigens, tumor-specific, 264
- Antihepatotoxic agents, 415
- Antihistamines, 205, 219, 221, 296–298, 374
- Antihypertensives, terazosin, 13, 15
- Anti-infective agents, 396–397
- Anti-inflammatories, 414
- Antimalarial drugs, 222
- Antimetabolites:
 - arotinoid Ro 40-8757, 411
 - characterized, 300
 - fluorouracil (5-FU), 410–411
 - methotrexate, 410
 - nucleophilic sulfur thios, 411
- Antimicrobial agents, 261, 400–401
- Antimigraine drugs, 202
- Antineoplastic effects, 413
- Antioxidants, 414–415, 418
- Antipsychotics, 217, 222
- Antisense nucleotides, 30
- Antistress agents, 414–415
- Antithrombotic agents, 314–315
- Antitrust litigation, 15
- Antituberculosis drugs, 221
- Antitumor:
 - agents, 105, 265, 405, 412, 414
 - antibiotics, 180
- Antiulcer drugs, search for, 298. *See also* Tagamet
- Anxiety disorders, 369
- API (active pharmaceutical ingredient), 2, 13
- Apomorphine, 76
- Apoptosis, 417
- Appetite stimulants, 220
- Applied sciences, 17–18, 36
- Aprepitant, 375
- Aptamers, 252
- Aquaporin-2, 316
- Aralkyl-substituted 4-hydroxypyrene, 226
- Areflexia, 385
- Arginine, 105
- Arginine vasopression (AVP), 315–316
- Argonaut Technologies, 24
- Aromatic nitro groups, 107
- Aromatic rings, 114, 124
- ArQule, 172–173
- Array technologies, 67
- Arrhythmias, 207, 221
- Artherosclerosis, 392
- Aryl:
 - boronic acids, 183
 - ethers, 188
 - nitriles, 187
 - oximes, 187
- 3-Arylindoles, 183
- Arylisocyanates, 190
- Aryloxypropanolamine template, classical, 63
- ASAT, 416
- Ashwagandha Rasayana, 417
- ¹⁸Asp, 78
- Asparagine, 32
- Asparagus crude saponins (ACSS), 419
- Asparagus racemosus*, 408–409, 416–417, 419
- Aspartate aminotransferase, 415
- Aspartic:
 - acids, 32, 361
 - proteases, 141
- Aspergillus niger* WB2346, 228
- Aspirin, 202, 417
- Asthma, 207, 314
- AstraZeneca, 207–208, 233
- AT₁ antagonists, 200
- Atenolol, 208
- Atorvastatin, 202–203
- ATPase inhibitors, 179, 310
- Attrition rate, 256
- Auto Desk, 48, 281
- Autoimmune diseases/disorders, 181, 249
- Automated Chemistry Environment (ACE), 147–148
- Automated synthesizers, combinatorial library
 - synthesis, 141, 143–144
- Automated tag reader/sorter, 143
- Autonomic nervous system, 296
- Auxophores, defined, 107
- Avidin, 245
- Avonex, 30
- Ayurveda/Ayurveda remedies, 406–407
- Azatadine, 205
- Azepinoindoles, 319, 321–322
- Azides, parallel solution-phase synthesis, 190
- 4-Azidobenzoic acid, 190
- Azithromycin, 6, 9–12
- Azmacort, 374
- Azole derivatives, 204
- Bacillus*:
 - anthracis*, 397
 - cereus*, 397
- Backup compounds, 80
- Bacteria, *see specific types of bacteria*
 - gram, 180
 - gram-negative, 397
 - inhibition of, 397
 - multidrug-resistant, 400
- Bacterial:
 - infections, 400
 - protein adhesins, 400
- Bait, posttranslational modification, 245
- Ball & Stick, 48, 281
- Barton's base, 187
- Bases, resin-bound, 185. *See also* Acid-bases
- Basis set, 20

- Baxter/Genetics Inst., 29
 Baycol, 392
 Bayer, 29, 207
 B cells, 408
 BCR-ABL tyrosine kinase, 262
 BCUT descriptors, 138
 Beckman rearrangement process, 9
 Behavioral and psychological symptoms of dementia (BPSD), 370
 Benazepril, 127
 BeneFIX, 29
 Bengamide, 266
 Benign prostatic hyperplasia (BPH), 13, 15
 Benzamidobenzoyl, 319
 Benzbromarone, 222
 Benzenesulfonamides, 170
 Benzenesulfonyl azide, 178
 Benzimidazolones, 178
 Benziodarone, 221–222
 Benzodiazepine(s):
 characterized, 319, 324–332
 libraries, 132
 receptors, 175–176, 215, 227, 369
 Benzodiazepinone, 355–356
 Benzofurans, 178
 Benzoic acid, 185
 Benzomorphanes, 216
 Benzothiophene, 150
 Benzoyl:
 chlorides, 170, 176
 group, 347, 349
 Benzylamine chiral auxiliary synthetic reagents, 71–74
 Benzyloxycarbonyl groups (Z-groups),
 erythromycin, 7
 Benzyl-protecting groups, 82
 Benzylsuccinic acid, 121
 BE 10988, 183
 Berlex, 30
 β -acetoxyoxetane system, 52, 82
 β -adrenergic blockers, 207–208
 β -adrenergic receptor blockade, 63
 β -blocking agents, 221
 β -C-Mannosides, 181
 β -diketones, 176
 β_1 -selective antagonists, 207
 Betaseron, 30
 β -thalassaemia, 390
 Betaxolol, 208
 Biacore, 249–250
 Bicarbonate, 387
 Bicyclo[2,2,2] octanes, 187
 Biginelli condensation, microwave-assisted, 178
 Bile acids:
 characterized, 387, 392–393
 sequestrants (BASs), 393–396
 Binary encoding system, 133
 Binding, 76
 Bins, combinatorial library design, 139
 Bioactive polymers, 401
 Bioassays, 213
 b ions, 241–242
 Bioavailability, 179–180, 202, 220, 223, 226–227,
 317, 330, 356, 372
 BioCarta, 271
 Biocatalysts, 154
 Biochemical:
 assays, 25, 27
 manipulation, 81
 pathways, 374
 sciences, 81
 Biochemistries, 67
 Biocombinatorial expression, 46
 Biodegradation, soft drugs, 21
 BioEdit, 270
 Bioengineering techniques, 26, 79, 379
 Biogen, 30
 Biogenic amines, 296
 Bioinformatics, 20, 40, 46–47, 81, 253–257, 284
 Bioisoelectronics, 124
 Bioisosteric exchange, 121
 Bioisostery, 20, 215, 221
 Biological assays, 191, 214
 Biological environments, impact of, 50–52
 Biological libraries, 237
 Biological-related sciences, 81
 Biological target, 135
 Biomarker(s):
 discovery techniques, 265
 significance of, 252, 256, 263–265
 Biomechanistic systems, 79
 Biomedical polymers, 383–384
 Biometabolism studies, 343
 Biomolecules, 58, 367
 Biopolymers, 130
 Biosynthesis, 105, 372
 Biosynthetic pathways, 217–218
 BIOTECH, 79
 Bio-Tech Gen., 29
 Biotechnology:
 advances in, 28, 35–36, 41, 65, 67, 79, 81, 84
 -derived therapeutic agents, 70
 Biotin/streptavidin, 252
 Biotropin, 29
 Bipyridine, 391
 Bis-acid chlorides, 191
 Bis-aryl sulfonamide, 150
 Bis-isopropylamino compound, 152
 Bisoprolol, 208
 Bisphosphonates, 207
 Black, James, Sir, 299
 Bladder toxicity, 416
 BLAST, 244, 269
 Bleomycin, 413

- Blood:
- clots, prevention of, 30
 - disorders, 30
 - level problems, 8
 - molecular conformation studies, 49
- Blood-brain barrier (BBB), 43, 57, 115, 139, 218–219, 222, 356
- Blood cell/marrow transplants, 30
- Blood pressure regulation, drug development
- example:
 - absorption, enhancement of, 124–126
 - analoging studies, pit viper-inspired peptides, 120
 - angiotensin-converting enzyme, inhibition of, 119, 121–123, 126
 - clinical SAR, 126–127
 - competition, 123–124, 126–127
 - historical background, 116
 - peptides, 120
 - peptidomimetics, 120–121, 128
 - renin-angiotensin-aldosterone system, 117–119, 123, 128
 - renin inhibition, 119
 - snake venom illustration, 117, 119–120
- Blue-chip drug, 61
- BMS:
- 181101, 371
 - 182874, 223–224
 - 192548, 228
 - 193884, 224
 - 207940, 224
- Boehringer-Ingelheim/Nes Rx, 30, 201
- Boehringer-Mannheim, 30, 208
- Bohdan Automation, 24
- Boiling point, 72
- Bone density, 386
- Bone marrow:
- chemoprotectants for, 413
 - GM-CFCs, 414
 - suppression, 411
 - transplant, 30
- Bopindolol, 208
- Botanical(s):
- antitumor agents, 418–419
 - characterized, 405
 - immunomodulators, 405–407
 - radioprotectants from, 418
- Botany, 45
- Bothrops jararaca*, 117, 119
- Bottlenecks, sources of, 26–27, 34, 154
- Bradycardia, 385
- Bradykinin, 118–119
- Brahma Rasayana, 417
- Brain:
- adrenocortex, 372
 - blood-brain barrier, 43, 57, 115, 139, 218–219, 222, 356
 - blood pressure regulation, 118
 - drug distribution, 114
 - neurochemistry, 369
 - positron emission tomography, 372
- Breast cancer, 30, 42, 176, 263–265, 370
- Bridged bicycle derivatives, 322–324
- Brimadmid, 219–220
- Bristol-Myers Squibb, 120, 200, 223
- Bromide hydrobromide, 175
- Bromohydrins, 188
- Bronchodilators, 170
- B3LYP, 20, 51
- B3LYP/6–31G*, 282
- Bulkyl aryl group, 64
- Burimamide, 304–305, 307, 309–310
- By-products, 3, 178, 185
- CAChe, 48, 281
- Caco cell lines, 57
- Calcium:
- channel blockers, 206–207, 215
 - characterized, 215, 387
 - intracellular, 316
 - oxide, 359–360
 - salts, 386
- Calpains, 182
- Cambridge Scientific, 48, 281
- Camptothecin (CPT), 43–44, 59
- Cancer, *see specific types of cancer*
- cells, characteristics of, 105, 370
 - chemotherapy, *see Chemotherapeutic agents*
 - diagnostic agents, 30
 - metastasis, 181, 408
 - statin treatment, 10
- Candesartan, 201
- Candidate drugs, 74, 108
- Candidiasis, 205
- Cannabinoid CB1 receptors, 220–221
- Captopril:
- analogs, 122–123
 - characterized, 200, 214
 - competition for, 127
 - side effects, 124
- Capture-release agents, 191
- Carbamate(s):
- azatadine, 205
 - characterized, 186
- Carbodiimide reagents, 184–185, 188
- Carbohydrates, 173, 244, 394, 407
- Carbon, 105–106, 367, 409
- Carbon dioxide, 145
- Carbonyl, 215
- 1,1'-Carbonyldiimidazole (CDI), 178
- Carboxamides, 187
- Carboxamidines, 302
- Carboxyalkanoyl-L-proline, 200
- Carboxy amide, 188

- 5-Carboxamido-1-benzyl-(3-dimethylamino-propyloxy)-1*H*-pyrazoles, 179
- Carboxybenzenesulfonyl chlorides, 170
- Carboxylate, 121
- Carboxyl groups, 121–122, 124–125
- Carboxylic acids, 72, 133, 141, 172, 349
- Carboxypeptidase, 120–121, 123
- Carcinogenicity, 66
- Cardiac arrhythmia, 116
- Cardia imaging agent, 30
- Cardioprotective antioxidants, 414
- Cardioside/Cardifolioside A/Carodiol, 415
- Cardiotonic substances, 217
- Cardiotoxicity, 413–414
- Cardiovascular disease/disorders, 116, 392
- Carfentanil, 341, 343
- Carotenoids, 416
- Carponone, 186
- Carvedilol, 208
- CAS Registry*, 10, 84
- Catalase, 414
- Catalysis, 185
- Catalysts, solid-supported (SSCs), 178
- Catalytic hydrogenolysis, 72
- Catch and release method, 185–187
- Catecholamines, 217
- Catecholates, 391
- Catechols, 392
- Cathepsin D, 140, 152
- Cathepsin G, 314
- Cationic polymers, 393–394
- CATS (chemically advanced template search), 215
- CB1 receptor antagonists, 220
- CC-1065/CC-1065 analogs, 180
- CDD (conserved domain database), 271
- CDD-0102, 31–32
- cDNA, 256
- CEA-scan, 30
- Celecoxib, 409
- Cell(s):
- adhesion molecules, 179
 - cell-cell interactions, 369
 - cell-surface adhesion, 314
 - culture assay, 215
 - cycle regulatory networks, 245, 257
 - proliferation, 407
 - repair, 407
 - trafficking, 369
- Cellobiose, 399
- Cellular biochemistry, 120
- Cellular functional assays, 318
- Centacor, 30
- Center for Disease Control, 353
- Centers for Health Research, 66
- Centocor, 29
- Central nervous system (CNS):
- active drug requirements, 140
 - azatadine analogs, 205
 - cannabinoid CB1 receptor, 220
 - characterized, 273–274, 316, 411
 - drug penetration into, 43
 - drugs for, 115
 - efficacy studies, 111–112
 - tetracycline and, 228
- Ceredase-glucocerebrosidase, 29
- Cerevastatin, 392
- Cerezyme, 29
- CERIUS, 48, 281
- Chalcones, 173–174
- Characterization, 239
- Charybdis Technologies, 24
- Chelators, metal, 390–392, 412
- Chemical:
- approaches, absorption process, 65
 - etching, 155
 - genomic strategies, 40
 - hurdles, 82
 - kinetics, 82
 - libraries, 237, 313
 - modifications, 80
 - reactivity, toxicology and, 67
 - structure, search engines, 57. *See also* Structure-activity relationship (SAR)
- Chemical Industry Institute of Toxicology (CIIT), 66
- Chemiluminescent nitrogen detection (CLND), 145
- Cheminformatics, 20, 46–49, 79, 81, 146, 280, 284
- Chemoprotectants/chemoprotectants:
- for antimetabolites, 410–411
 - for anthracyclines, 414
 - botanical immunomodulators, 414–417
 - characterized, 405, 419
 - drug targets, 409
 - goal of, 409
 - immunomodulation and, 409–410
 - thiol-based, 411–414
- Chemosensitizer drugs, 42, 44
- Chemotherapeutic agents, *see also specific medications*
- characterized, 9, 235, 405–406
 - NCE, 40
 - P-glycoprotein pump (Pgp), 42, 44, 83, 151–152
 - smart bombs, 58
 - topotecan, 43
- Chemotherapy:
- anemia and, 29
 - benefits of, generally, 377
 - blood disorder treatments, 30
 - for leprosy, 222
- Chemotoxicity, 419
- CHEM-X, 146
- Cherry picking, 139
- Cherwell Scientific, 48, 281
- Children, *see* Pediatrics

- Chiral:
 auxiliary synthetic reagents, 71–74
 pyrazolines, 221
- Chiron Technologies, 24, 30
- Chitobiose, 399
- Chloride, 387
- Chlorimipramine, 217
- Chlorine, 215, 358
- 8-Chloro derivatives, 205
- Chloromethylated polystyrene, 134
- Chlorpromazine, 214, 221, 215, 217, 222
- Cholebine, 396
- Cholesterol:
 levels, 202, 392–396
 -lowering agents, 10, 392–396
 metabolism pathway, 393–396
- Cholestyramine, 3393, 98
- Cholinergic:
 agonists, 224
 excitatory neurotransmission, 204
- Chromaffin tissue, 217
- Chromatography:
 applications, generally, 72
 electron-capture gas, 133
 flash, 142, 145
 flash-column, 322
 fluoroFlash chromatography, 190
 high-performance liquid (HPLC), 45, 143, 145, 240–242, 257
 ion-exchange, 300
 liquid, 264
 supercritical fluid (SFC), 245
- Chronic granulomatous disease, 30
- Chronic hepatitis C infections, 30
- Chronic inflammatory process, 407
- Chronic myeloid leukemia (CML), 262
- Chronic renal failure and, 386–389
- Chronic toxicity, 107, 109
- Chymase, 314
- Ciba-Geigy, 201
- CICLOPS, 146
- Ciglitazone, 200
- Cilazapril, 127
- Cimetidine, *see* Tagamet
 characterized, 214, 219–220, 304
 discovery of, 307–308
 peptic ulcer disease treatment, 308–309
- Cinnamic methyl ester, 152
- Cirrhosis, 316
- Cisapride, 203–205
- Cisplatin, 411–412
- CL-385004, 319
- Clarithromycin, 6–8, 10, 12
- Classical inhibitor studies, 27–28
- Classical synergies, 60
- Cleavage:
 asymmetric, 72
 characterized, 264
 enalaprilat, 124
 mass spectrometry analysis, 242
 peptide bonds, 120–121
 photolytic, 133
 in screening combinatorial libraries, 132
- Clinical candidate, defined, 108
- Clinical candidate drug:
 cimetidine, 307–309
 dynamic structure-activity analysis, 305–306
 imidazole tautomerism, 306–
 sulfur methylene isosterism, 306–307
 thiourea, isosteres of, 307–308
- Clinical efficacy, 109
- Clinical investigations, 221–223
- Clinical proof of principle, 28
- Clinical SAR, 126–127
- Clinical testing, 26
- Clinical trials:
 amifostine, 413
 biomarker profiles, 264
 characterized, 2, 235–236, 262, 398–400
 discovery process, 235–236
 remifentanyl, 349–350
- Clodronate disodium, 208–209
- cLogP, 191
- Clopidogrel, 215
- Closed-shell molecules, 50
- Clostridium*:
difficile, 397–400
parvum, 401
perfringens, 397
- Clots/clotting factors, 29
- Clustal, 270
- Cluster computing, 254
- Clustering methods, combinatorial library design,
 139
- Cocaine, 216
- Cocktail vaccine, 249
- Colchicine, 203
- Colesevelam hydrochloride, 394
- Colestamide, 396
- Colestipol, 393, 398
- Colitis, 399
- Collision-induced dissociation (CID), 241–242
- Colon cancer, 176
- Colorectal cancer, 413
- Combinatorial biosynthesis, 45
- Combinatorial chemistry:
 case histories/illustrations, 149–154
 combinatorial libraries, design of, 135–141
 drug discovery, role in, 135–137, 149–154
 future directions for, 154–155
 historical perspectives, 130–131
 information resources, 156
 key developments in, 130
 lead optimization, 136, 151, 267

- library screening strategies, 131–132
- library synthesis, 141–146
- management strategies, 146–148
- overview of, 24, 26–28, 36, 39, 83, 129–130, 155, 214, 260
- small molecule synthesis, 132–133, 135
- solid-phase chemistry, 133–135
- as standard tool, 148–149
- trends in, 135
- Combinatorial libraries:
 - characterized, 20, 26, 79
 - design of, 134–141
 - encoded, 132
 - indexed, 132
 - optimization, 136–137, 148
 - orthogonal, 132
 - screening strategies, 131–132
 - synthesis tools, 141–146
 - virtual, 137–138, 140
- Combinatorial mixtures, 81
- Combinatorial revolution, 129
- Commercialization, impact of, 2
- Compactin, 202
- Comparative molecular field analysis (CoMFA), 20, 56
- Competition, significance of, 123–124
- Complementary medicine, 407–408
- Co-morbidity, 374
- Compound(s):
 - action potential (CAP), 412
 - attrition rate, 236
 - hits, attributes of, 80–81
 - libraries, *see* Compound libraries
 - overload, 27
 - profiling, virtual, 58
 - surveys, 54
- Compound libraries:
 - characterized, 24, 33, 37, 39, 45–46, 69, 80–81, 108
 - virtual, 55–56, 79, 284
- Comprestatin A4 phosphate, 376
- CompuDrug, Inc., 276
- Computational biology, 253–256
- Computational chemistry, 260–261
- Computational chemists, role of, 81, 214
- Computational methods, 313
- Computational structure determination, protein
 - structure analysis, 247
- Computational studies, molecular conformation
 - assessment, 47, 50
- Computational technologies, molecular
 - conformation studies, 53, 55–57
- Computed tomography (CT), 367
- Computer hardware, solid-phase synthesis, 134
- Computer modeling, combinatorial chemistry, 135
- Computer software programs:
 - Automated Chemistry Environment (ACE), 147
 - CAS Registry, 10
 - combinatorial library design, 137
 - combinatorial library specification, 146
 - public domain software tools and databases, 269–271
 - RADICAL, 146–147, 149
 - solid-phase synthesis, 134
 - spectrum prediction, 145–146
 - structure prediction, 247
- Condensation:
 - implications of, 107
 - multicomponent, 177
 - polymers, 394
- Conformational assessment, 282
- Congestive heart failure (CHF), 179, 223, 316, 332
- Conivaptan, 317
- Contemporary drug discovery:
 - barriers to success, 104
 - cost of, 104
 - example of, 116–128
 - hit required criteria, 108–116
 - suitable lead substance, characteristics of, 104–108
- Continuing education programs, 82–83
- Controlling the size of the haystack, 55
- Coomassie blue staining, 242
- Copolymers, 400
- Copper, 391
- Core structure, combinatorial library design, 137
- Corneal deposits, 221
- Coronary dilators, 221–222
- Coronary heart disease, 392
- COR Therapeutics, Inc., 315
- Corticotrophin releasing factor (CRF), 225, 316
- Cortisol levels, 372, 416
- Cost, drug development process, 109
- Counterions, 72
- Coupling:
 - characterized, 143, 187
 - combinatorial chemistry, 152
 - cycles, 131
- COX-2 inhibitors, 10, 13–15
- c(Pro-Tyr-D-Trp-Lys-Thre-Phe), 151
- Creatine levels, 182
- CRF antagonists, 225
- Critical path, implications of, 317–318
- Crocetin*, 416
- Cross-reactivity, 262
- Crystal lattice, 49
- Crystallization, 75, 79, 344, 347, 360
- CSC Chem 3D/Chem 3D Plus, 48, 281
- C3-convertase, 415
- Curacin, 178
- Curative treatment, 79
- Curtius conversion, 82
- Cyanide reagent, 347
- Cyanoguanidines, 304, 308

- Cyanohydrin, 347
 Cycle time, 154
 Cyclic adenosine monophosphate (cAMP):
 characterized, 75–78, 316, 372
 phosphodiesterase enzymes, 75–78
 Cyclic (depsi)peptides, 179
 Cyclic phosphates, 75
 Cycline-dependent kinase (cdk), 176, 179
 Cyclin E inhibitors, 179
 Cyclization:
 intramolecular Wittig, 175
 parallel solution-phase synthesis, 170, 172,
 174–175
 Cycloaddition reaction, 182, 188
 Cyclopentadiene, 322
 Cyclophosphamide, 412–413, 416
 Cyclopropyl:
 analogs, 76
 characterized, 357
 dopamine, 77
 template, 82
 Cyclopropylamine, 357, 359–360
 CYP, 274–275
 Cystein oxidation, 243
 Cysteine proteinases, 182
 Cystic fibrosis, 29
 Cytochrome P450, 51, 73, 283
 Cytogen, 30
 Cytokines, 369, 415, 418
 Cytoprotection, 419
 Cytosine, 105
 Cytotoxicity, paclitaxel (PAC), 42

 Dainippon, 204
 Damstadt, 208
 Data, generally:
 -driven exploration, 253
 fuzzy, 52, 56, 283
 genomic, 47
 handling, combinatorial library management, 146
 integrity, 254
 mining, 54, 254, 284
 pk, 28
 profiling, 41, 59–61, 67, 70, 79, 139
 validity of, 234, 254, 256–259, 266
 Database(s):
 Ayurvedic, 407
 combinatorial library design, 140
 efficacy, 41
 HTS-generated, 59
 knowledge-generating structural, 36
 management, 254
 pharmacogenetic, 40
 public domain, 269–271
 2D structure-metabolism, 39
 toxicology, 66
 virtual, 55–56

 DAVID, 270
 DEAD, 188
 Dealkylation, 356–357
 Debenzylation, 72–73
 Debrisoquine, 275
 Decalin, 202
 Decarboxylation, 218–219
 DEC (1,2-dichloroethane), 325
 Dechlorination, catalytic, 358–359
 Deconvolution, 131–132, 135, 150–151
 Deep View, 270
 Dehydration, 111, 185, 187
 Delapril, 127
 Dementia, 369–370
 Density functional theory, 51
 Deoxyuridine 5'-monophosphate, 105
 Depression, 369, 372
 Deprotection, 143, 185
 Deprotonation, 187
 DEREK, 66
 Desferrioxamine, 390
 Desloratadine, 205
 Desmethyl-deoxy-minaprine, 225
 Desmethylminaprine, 228
 Dess-Martin reagent, 166
 Detector, in mass spectrometry analysis, 241
 Detoxification, cellular, 407
 Deuterium labeling study, erythromycin, 3–4
 Development costs, 136
 Dextrazoxane, 414
 Diabetes:
 insulin-sensitive, 29
 statin treatment, 10
 Diabetic neuropathy, 29
 Diacylglycerol, radiolabeled, 369
 Diadzein, 46
 Diagnoses, future events prediction process, 79
 Dialysis, 386
 Diamines, 151
 Diastereoselectivity, 322
 Diastereomers, 72
 Diazepam, 215, 227
 Diazepinones, 355
 Diazo compounds, 178
 Dichloroaminopyridine, 358
 2,6-Dichloro-9-cyclopentylpurine, 176
 Dichloropurine, 176
 3,6-Dichloropyridazine, 177
 Didanosine, 361
 Didemethylated compounds, 175
 Diels-Alder reaction, 137
 Dietary phosphate, 387
 Dietary supplements, *see* Nutraceuticals
 Diethyldithiocarbamate (DDTC), 412–413
 Diffraction studies, 75, 135
 Diffractometer, 75
 Diffusion, 111–112, 114

- Digitalis, 116
- Diglyme, 360
- Dihydrofolate reductase, 105–106
- Dihydrofolic acid, 105–106
- 3,5-Dihydroxyheptanoic acid derivative, 202
- Dihydroxyphenylalanine, 218
- 3,4-Dihydroquinoxalin-2-ones, 183
- Diisopropylethylamine, 187
- Dimers, 180
- Dimethoxybenzoyl chlorides, 174
- Dimethylformamide (DMF), 178, 360
- 2,5-Dimethylfuran, 146
- Diovan, 215
- DIP, 271
- Dipeptides, 117, 121
- Diphenhydramine, 298
- Dipyrido compounds, 356
- Dipyridodiazepinone structure, 357
- Directing distribution, 58–59
- Discovery chemists, 105
- Discovery process:
 - case study, 265–266
 - clinical trials, 235–236, 263–265
 - efficiency of drug, 236
 - emerging technologies, 236–237
 - financial considerations, 25, 104, 236, 256
 - genomics, 237–238
 - high-throughput screening (HTS) approaches, 236–237
 - hits, screening for, 234, 259–261
 - hurdles in, 236
 - lead optimization, 234, 261–262
 - libraries, 80
 - pharmacology, 235, 262–263
 - proteomics, 238–248
 - pyramid, 109
 - target identification and validation, 234, 256–259, 266
 - time frame for, 236, 256
 - toxicology, 235
- Discrete compounds, 135
- Disease, *see specific diseases*
 - biomarker profile, 264
 - model, 236–237
 - vs. normal state, 263–264
 - pathology, 259
- Displacement reactions, 185
- Distamycin, 178
- Distribution, 18, 39, 109, 113
- Disulfiram (DSF), 413–414
- Diuresis, 317
- Diuretics, 116, 123, 324
- Diversity, combinatorial library design, 137–139
- Diversomer technology, 132, 143
- Divide, 131
- DMP-504 colestimide, 394
- DNA:
 - alkylation, 411
 - array technology, 252
 - characteristics of, 105
 - duplex, 180
 - microarrays, 250
 - polymerases, 355–356, 360
 - synthesis, 419
 - toxicity and, 107–108
- DNAse, 29
- DOCK, 140
- Docking interaction, 76, 79, 105, 121–122, 127, 283
- Domain, defined, 244
- Donepezil, 371
- Donors:
 - H-bond, 140
 - soft, 391
- DOPA, 219
- Dopamine:
 - biosynthesis and metabolism, 218
 - characterized, 218–219, 371
 - receptor antagonist, 203, 375
 - receptor ligands, 82
 - receptors, 75–78, 215, 370, 372
- Dosage:
 - dose-dependent suppression, 226
 - dose-ranging studies, 25
 - dose-response curve, 319
 - dose-response relationship, 296, 375
 - serum protein binding, 114
 - toxicity and, 107
- Double displacement reaction, 170
- Doxorubicin, 414
- Dreiding molecular mechanics, 47, 280
- Dronabinol, 220
- Drug(s):
 - administration, user-friendly, 79
 - defined, 108
 - delivery system, 263
 - design components, 71, 260–261
 - efficacy, 264–265
 - interaction profile/interactions, 61–62, 200, 205
 - metabolism, *see* Drug metabolism
 - structural themes, 31
- Drug-binding systems, 114
- Drug-biological interface, 57
- Drug-drug partnering, 62
- Druglike/druglikeness:
 - defined, 20, 139–140
 - implications of, 227
 - nondruglike distinguished from, 55
- Drug metabolism:
 - biological environments and, 50–52
 - databases, *see* Drug metabolism databases
 - high-throughput screening studies, 284, 286, 288
 - implications of, 51–52, 61, 275
 - nuclear magnetic resonance studies, 282–284

- Drug metabolism: (*Continued*)
 systematic studies, 278
 x-ray studies, 282–284
- Drug metabolism databases:
 characterized, 273, 287–288
 future directions for, 280, 282–287
 historical perspective, 275–276
 industry survey about, 278
 informational fields, 287 (fig.)
 hurdles for, 286
 metabolic and excretion capabilities, 274
 metabolic capabilities displayed by human
 phenotype, 275
 present status of, 276, 278–280
 xenobiotics, 286
- Drug-receptor/active site docking, 57, 286
- Drug-receptor interactions, 19
- Drug-receptor theory, 105
- Drugs of interest (DOIs), 374
- Drug-target interaction, 372, 375
- Duocarmycins, 180
- Duodenal ulcers, 296, 307, 416
- DuPont, 201, 208, 216
- Duration of action, significance of, 13
- Dynamic combinatorial libraries (DCLs), 154
- Dynamic energy relationships, 52–54
- Dynamic structure-activity analysis, 305–306
- Dyspepsia, 310
- Early phase analogs:
 ACE inhibitors, 199–200
 antimigrane drugs, 202
 AT₁ antagonists, 200
 HMG-CoA reductase inhibitors, 202
 insulin sensitizers, glitazones, 200, 202
 proton pump inhibitors, 200
- Echinacea purpurea*, 408
- Economic considerations, 13, 25, 104, 236, 256
- Edema, 316–317, 332
- Edisonian methods, 314
- Edman sequencing, 241, 257
- Efficacy:
 defined, 110
 in drug development process, 109–110, 264–265
 following oral administration, 110–112
 potency compared with, 110
 pursuit of, 40–46
 structural manipulation and, 71
 suitable lead substances, 104–105
 test/testing, 25, 79, 264
- EGF-R tyrosine kinase, 373
- Ehrlich ascites carcinoma, 418
- Elderly metabolic capabilities, 275
- Electrolyte balance, 385
- Electromagnetic field separation, in mass
 spectrometry analysis, 241
- Electron-capture gas chromatography, 133
- Electronic physicochemical properties, 63
- Electronic topography, 75
- Electrospray ionization (ESI), 241–242
- Electrostatic:
 interaction, 387, 398
 potential, 20, 37, 70, 73, 77, 84
- Eletriptan, 204
- EL-4 leukemia, 413–414
- Eli Lilly Company, 29, 299–300
- Elimination structural relationship (ESR),
 64
- Emblca officinalis*, 409, 417
- Emergent activity, defined, 214
- Emerging technologies, 237
- Enalapril, 200
- Enalaprilat, 124–125, 127
- Enantiomers, 13, 327
- Endotheline ET_A receptors, 223–224
- Endothelins (ETs), 77–78
- Endotoxins, 397
- 5-*Endo-trig* anti-Baldwin ring closure, 172
- End-stage renal failure, 386
- Entacapone, 219
- Enterobactin, 391
- Entrez:
 SNP, 270
 Taxonomy, 270
- Enzymatic assays, 234
- Enzyme(s), *see specific enzymes*
 exploitation of, 71
 inhibitors, 300
 kinetics, 361
 -substrate interactions, 106
- Epichlorohydrin cross-linked polyallylamine,
 389
- Epogen, 29
- Epoxide, 73
- Eprosatan, 201
- Equilibrium, significance of, 51, 282
- Erbix, 373
- Ergosterol, 206
- Erythema nodosum leprosum, 222
- Erythrocytes, 399
- Erythromycin, 3–8, 10, 12, 182, 226
- Erythropoietin-related growth factors, 29
- Escherichia coli* (*E. coli*), 252, 397
- Esmolol, 63–65, 208, 342
- Esterases, 65, 124, 341–342
- Esters, 63–64, 124, 176
- Estradiol, 369
- Estrogen receptor modulation, 409
- Ethanol, 417
- Ether extracts, 408
- Ethics, 84
- Ethnopharmacology approach, 406–407
- Ethyl acetate, 348
- Ethyl 1-diazo-2-oxopropylphosphonate, 189

- Ethylenediaminetetraacetate razoxane (ICRF-187), 414
- Ethylene glycol, 347
- Ethyl ester, 124
- 5-(3-Ethyl-1,2,4-oxa-diazol-5-yl)-1,4,5,6-tetrahydropyrimidine), *see* CDD-0102
- Etidronate sodium, 208–209
- European Chemicals Bureau (ECB), 66
- European Organization for Research and Treatment, 377
- Evaporation, 142, 144–145, 155
- Evaporative light-scattering detection (ELSD), 145
- Excess reagents, 131
- Excretion, 18, 39, 65, 79, 109, 115, 118
- Exotoxins, 397
- Expasy-SwissProt, 271
- Experientia*, 5
- Extant impurities, 3
- Extended Hückel calculations, 20, 47
- Fabrication techniques, combinatorial chemistry, 155
- Factorial design methods, 141
- Fail fast drug candidates, 262
- Famotidine, 219–220
- Fast-second projects, 315
- Fatty acids, 114
- FDA, *see* U.S. Food and Drug Administration (FDA)
- Fe(II), 391
- Feedstock, biochemical, 42
- Feline leukemia virus, 356
- Felkin's iridium catalyst, 186
- Felodipine, 207
- Fentanyl, 341–343
- Fenticonazole, 206
- Ferrer, 206
- Fibrinogen receptor, 314
- 1536-well microplates, 21
- Filtration, 131, 178, 360
- Final lead compounds, 80
- Fingerprinting, toxicology studies, 67
- First-pass effect, 274
- FKBP12 inhibitors, 180
- Flash chromatography, 142, 145, 322
- Flavanoids, 178, 188, 418
- Flavones, 46, 175–176
- Flavoproteins, 371
- Fluconazole, 205–206
- Fluidic synthesizers, 142
- Fluorescence detection methods, 132, 155
- Fluorescence polarization spectroscopy, 398–399
- Fluorescent labeling, 252
- Fluorocarbon fluid, insolubility of, 134
- Fluoro*Flash* chromatography, 190
- 2-Fluoronitrobenzenes, 178
- 4-Fluorophenyl, 202
- Fluoroquinolone antibiotics, 375
- Fluorouracil (5-FU), 410–411
- Fluorous synthesis, 190
- Fluvastatine, 202–203
- Focused libraries, 37, 140
- Folk medicine, 19
- Food:
- absorption, 111
 - poisoning, 397
- Formulability, 109
- Fosinopril, 127
- Fractionation, 239, 251
- Free energies, 51, 282
- Free radicals:
- characterized, 390, 412, 415, 419
 - quenching, 407
- Front-line testing, 58, 79
- Frovatriptan, 204
- Fucosyltransferases, transition-state inhibitors, 181
- Functional analogs, 215
- Functional analysis, 245
- Functional groups, 107, 139
- Functional protein arrays:
- advantages of, 250–251
 - disadvantages, 251
 - implementations of, 250, 252
 - underlying principles, 250
- Functional protein microarrays, 262–263. *See also* Functional protein arrays
- Funding sources, public-sector, 33
- Fungistatic agents, 205
- Furan, 13, 220
- Fusion tags, 250
- Fuzzy data, 52, 56, 283
- GABA receptors, 372
- Gador and Henkel, 209
- Gallbladder, 393
- Gas-phase equilibrium, 51, 282
- Gastric:
- acid, 296–300, 303, 308–310
 - parietal cells, 200
 - ulcers, 220, 296, 409, 416–417
- Gastrin, 297–298, 300
- Gastroenterology, 310
- Gastroesophageal reflux disease, 204
- Gastrointestinal (GI):
- disorders, 181
 - motility assays, 6
 - tract, 110, 118, 205, 384–386, 391, 393, 397, 401
- Gastroprokinetic drugs, 204
- Gaucher's disease, 29
- Gaussian 98:
- applications, 20, 47, 51
 - MOPAC, 280
 - package, 282
- Gene-based disease, 80
- GeneCard, 269

- Gene expression, 237–238
 Gene Logic, 66
 Genentech, 29–30
 Gene regulation, 370
 Generic companies/drug manufacturers, 3, 15
 Generic library, 140–141
 Gene therapy, 80
 Genetic disorders, 390
 Genetics Inst., 29–30
 Genetic toxicity, 38, 108
 Genetropin, 29
 Genistein, 46
 Genital warts, 30
 Genomic data, 47
 Genomic Health, Oncotype DX diagnostic, 263
 Genomics, 18, 20, 26, 28, 33–34, 38–39, 58, 67, 79, 83, 237–238, 313, 401
 Genotoxicity, 228, 416
 GenScan, 269
 Gentili/Merck, 209
 Genzyme Corporation, 29, 389
 Gilson, 24
 Ginseng abuse syndrome, 408
 Glass/glassware, 155, 170
 GlaxoSmithKline, 201–202, 204, 207, 310
 Gleevec, 262–263
 Glitazones, 200, 202
 Glucose, 115, 371
 Glucuronic acid, 114
 Glutamate carboxyls, 105
 Glutamine pyruvate transminase, 419
 Glutathione peroxidase inhibition, 409
 Glutathione *S*-transferases (GST), 416–417
 Glycoproteins, 244, 314
 Glycosides, 400
 Glycosylation, 243, 264
 Gonal-F serono, 29
 Gram bacteria, growth inhibition, 180
 Gram-negative bacteria, 397
 Granulocyte macrophage colony stimulating factor (GM-CSF):
 characterized, 30, 415
 progenitor cells, 414
 Granulocytopenia, 307–308
 Graph theory, 283
 Green chemistry, 70–71
 GRID, 140
 Growth hormones, 29
 GT, 399
 Guanidine, 302, 308
 Guanidine isostere, 304
 Guanidinium salts, 386–387
 Guanidino, 220
 Guanine, 105
 Guanylate cyclase, 179
 Guanylhistamine, 219
 Guilt by association, 245

¹H, 170
 Half-life, significance of, 13, 238
 Haloaromatic tags, 133
 Halogen, 114
 Halogenation, 187
 Haloperidol, 215
 Hammett equation, 309
 Hässle, 207–208
 Hay fever, 298
 Head and neck cancer, 413
 Health policy, 80
 Heart:
 arrhythmia, 116
 cardiovascular disease/disordres, 116, 392
 congestive heart failure, 179, 223, 316, 332
 coronary artery disease, 392
 drug distribution in, 114–115
 failure, 116
 ischemic cardiomyopathy, 316
 HEK-293 cells, 318
Helicobacter pylori, 310
 Hematological toxicity, 413
 Hemochromatosis, 390
 Hemodialysis, 389
 Hemodynamics, 316
 Hemolysis, 114, 397
 Hemophilias, 29
 Hemopoietic agents, 414
 Hepatic disease, 316
 Hepatotoxicity, 415
 Herbal medicines/remedies, 21, 59–62
 Herceptin, 30, 265
 Heteroatoms, 77
 Heterocycles, one-step construction of, 182
 Heterocyclic statins, 202
 Hexapeptides, 131–132
 High blood pressure, *see* Hypertension
 High-performance liquid chromatography (HPLC):
 applications, 240–242, 257
 combinatorial library synthesis, 145
 phytoalexins studies, 45
 preparative, 143
 High-throughput, *see* High-throughput screening (HTS)
 assays, 28
 chemistry, commercial equipment, 142
 protein interaction studies, 262
 synthesis, combinatorial libraries, 145–146
 technologies, 265
 High-throughput screening (HTS):
 absorption, *see* Absorption high-throughput screening (AHTS)
 ADMET profiling, 69–70
 alternatives to, 213–229
 applications, 33, 108, 148, 155, 234, 236–237, 245–246, 248, 257, 260, 275, 300, 313–314, 355

- assay development, 41, 45
- combinatorial chemistry approach, 26–27
- defined, 20, 24
- discovery process, 213
- drug discovery and development, 79, 81
- drug metabolism studies, 284, 286–288
- efficacy screen, 55, 84
- efficacy surveys, 27, 33, 35–37, 54–55, 64, 67, 81
- future directions for, 79
- intellectual property (IP), 83
- microengineering, 41
- multicomponent synergies, detection of, 62–63
- process, 41–42, 81, 245–246
- ¹⁶HIS, 78
- Histamine:
 - biological approach to histamine antagonist, 299–300
 - characterized, 296–297, 301–302
 - receptors, 219, 298–299
- Histaminergic H₂ antagonists, 214, 222
- Hit(s):
 - biopharmaceutical quality of, 214
 - defined, 108
 - drug development criteria, 108–116
 - generation of, 191
 - screening for, 234, 259–261
 - structure, 73–74
 - validation criteria, 213
- HIV-1 RT (reverse transcriptase), 353–355, 357, 360
- HIV-2:
 - RT, 361
 - SIV, 356
- HL-60 cells, 419
- HMG-CoA reductase inhibitors, 202, 214, 392–393
- HOBt, 184–185
- Hoffman-LaRoche, 30
- Homcy, Charles, Dr., 315
- Homeostasis, 18, 38, 385
- Homologene, 270
- Homologous proteins, 244, 261
- Homology modeling, 135, 140, 247
- Homophenylalanine esters, 127
- Hormones:
 - estrogen, 409
 - fertility, 29
 - growth, 29
 - neurohormones, 218
 - steroidal, 214
- Horner-Emmons reagent, parallel solution-phase synthesis, 187
- Horner-Wadsworth-Emmons olefination, 189
- Host defense mechanisms, 407
- Host-guest:
 - compatibilities, 112
 - complex, 105
 - relationships, 116
- Hot spots, 67
- 5-HT₄, 204
- 5-HT_{1B/1D} agonist, 202
- 3-(1*H*-tetrazol-5-yl)-4(3*H*)-quinazolinones, 172
- HTS efficacy process, 41–42
- HTS/UHTS methodologies, 79
- Humalog, 29
- Human studies:
 - clinical trials, 349–350, 398–400
 - dihydrofolate reductase, 105–106
 - drug metabolism database, 51, 275
 - esterases, 63
 - genome, 21, 135
 - GI endothelial system, 58, 71
- Human Genome Project, 135
- Human immune deficiency virus type 1 (HIV-1), 353–354, 356
- Human somatostatin receptors (hSSTR1–5), 151
- Humatrope, 29
- Humulin, 29
- HUN-7293 analogs, 179
- Hydantoin, 132
- Hydrazides, 170
- Hydrazine, 170, 185, 187
- Hydrogen:
 - bond/bonding, 4–5, 20, 50, 54, 78, 112, 138, 140, 282, 302, 387
 - characterized, 114
 - groups, 357
- Hydrogenation, 344
- Hydrogenolysis, 7, 72–73, 349
- Hydrolysis, 77, 114, 118, 120, 152, 344, 347–349
- Hydrophilic drugs, 111
- Hydrophilicity, 394, 397
- Hydrophobicity, 20, 152, 394, 397
- Hydroxamates, 391
- Hydroxamic acid, 392
- Hydroxy acid, 202
- Hydroxy(ethyl)amine isotere, 152
- Hydroxyl:
 - groups, 5–6
 - radicals, 390, 415
- Hydroxylamines, 107, 174
- Hydroxylase, 372
- Hydroxylation, 43
- Hydroxymethylglutaryl (HMG), CoA reductase, 202
- HyperChem, 48, 281
- Hypercholesterolemia, 202
- Hyperkalemia, 385–386
- Hyperparathyroidism, 386
- Hyperphosphataemia, 386–387
- Hypertension:
 - characterized, 116, 207, 217, 332
 - statin treatment, 10
 - terazosin, 13, 15
- Hypnosis, 340
- Hypnotics, 222, 339–340, 349
- Hypoglycemic effect, 221

- Hyponatremia, 316
Hypotensives, 217
Hypothalamus, 315
Hypothesis-driven methodology, 253
- Ibandronate sodium, 209
ICI Pharmaceuticals, 208, 298
ICRF-187, 414
IDEC, 30
Identification, in proteomics, 239
Idiosyncratic problems, in drug development process, 109
Ifosfamide (IFX), 412–413
Imidapril, 127
Imidazole(s), 152, 303, 306, 309–310
Imidazole-5-acetic acid derivatives, 200
Imidazolic ring, 220
Imidazoline receptor, 372
Imidazolinones, 182
Imidazolone system, 75, 77
Imidazolylalkylcarboxamidines, 301
Imidazolylalkylguanidines, 301
Imidazolylalkylisothiourreas, 301
Imidazolylalkylthiourreas, 303
3-Imidazolylcarbolines, 181
Imidazopyridazines, 176
Imidazo[2,1-*b*]quinoxolin-5-(3*H*), 170
Iminium salts, 174
Imino ethers, 172
Imipramine, 214, 217
Immune systems, 407
Immunex, 30
Immunity, cell-mediated, 408
Immunization techniques, 252
Immunodulatory agents, 415
Immunology, 245, 414
Immunomedics, 30
Immunomodulators, 222, 406–407, 409, 414, 416, 418
Immunoprecipitation, 239240
Immunoprotection, 416
Immunostimulation, 407
Immunosuppression, 370, 408
Immunotherapy, 370
Immunotoxicity, 413
Indian Ayurveda, 406–407
Indian Herbal Pharmacopoeia, 414
Indigenous herbal drug formulations, 417
Indolozepine, 321
Indolobenzodiazepine derivatives, 319
IND phase, 28
Infection, 40, 46. *See also specific types of infections*
Infectious disease, 414
Infergen, 30
Inflammatory diseases, 181
Influenza neuramidinase (NA) inhibitors, 181
Influenza virus neuraminidase inhibitors, 261
Informatics, 253, 257. *See also* Bioinformatics
Information technology (IT), 46–47
Inhibitor(s), *see specific types of inhibitors*
A-192558, 181
characterized, 105–106, 111, 260
Injectable medications, 113
Insulin:
characterized, 29
mimetics, 213
sensitizers, 200, 202
Integrins, 314
Intellectual property (IP), 18, 83–84, 115
Interdisciplinary research, 82–83
InterDom, 271
Interferon- α , 30
Interferon- β , 30
Interferon gamma (INF-(γ)), 30, 415
Interferon Sci, 30
Interleukins:
characterized, 30
Interleukin-1 (IL-1), 416–417
Interleukin-2 (IL-2), 415
International pharmaceutical community, 26
International Program on Chemical Safety/
Organization for Economic Cooperation
(IPCS/OECD), 66
International Toxicology Information Center (ITIC),
66
International Uniform Chemical Database
(IUCLID), 66
InterPro, 271
Intracellular localization, 67
Intravenous administration, 6, 13
Intrinsic activity, 76
Intron, 30
Inventorship, 19
Invitrogen, 242
Iodohydrins, 188
Iodonium diacetate, 186
Ion-exchange:
characterized, 182, 185, 187–188
chromatography, 300
Ionization/ionization chamber, 111–112, 125, 241
Ioselectric point, 240
Iqbal multicomponent procedure, 177
Irbesartan, 201
Iron:
cellular, 414
chelating polymers, 392
overload disorders, 389–392
Irori AccuTag-100 system, 143
Irradiation, 188, 413
Ischemic cardiomyopathy, 316
ISIS/Ciba, 30
Isocyanates, immobilized, 185
Isoflavones, 46, 416
Isoflurane, 349

- Isoleucine, 361
- Isomaltotriose, 399
- Isomerization, 185–186
- Isoniazide, 221
- Isopelletierine, 415
- Isopropyl acetate, 349
- Isopropyl groups, 215
- Isopropylsubstituents, 202
- Isopycnic suspensions, 144
- Isosteres, 20, 304
- Isothiourea, 302
- Isoxazolines, 174
- Itraconazole, 206
- IUPAC, 199

- Janssen, Paul, 204, 206, 341
- Janssen Pharmaceutica, 341
- Japanese Kampo, 406
- Jarvis-Patrick clustering, 139, 152
- Jaundice, 222
- Johnson & Johnson, 317

- Kayexalate, 386
- KEGG (Kyoto Encyclopedia of Genes & Genomes), 270
- Kerolides, 182
- Ketoconazole, 204–206
- Ketones:
 - characterized, 177, 185, 187–188
 - inhibitors, 182
- Kidney(s):
 - damage, 116
 - drug distribution, 115
 - filtration, 117–119
 - functions of, 113
 - stones, 385
 - transporters in, 65
- Kinases, 27, 137, 176, 179, 262, 361, 373
- Klebsiella pneumoniae*, 400
- Knowledge-generating mining paradigms, 54, 284
- Knowledge systems, 84–85
- KoGENate, 29
- KQAGD sequence, 314
- Kramerixin, 178

- Laboratory, *see specific corporations*
 - conventional environment, 154
 - determination, in protein structure analysis, 246–247
 - information management systems (LIMS), 254
- Laborit, 221
- Lacidipine, 207
- Lactate dehydrogenase, 415
- Lactone, 202
- LAF389 case study, 257, 265–266
- Lansoprazole, 200–201

- Large-scale stereoselective synthetic methodologies, 18
- Laser microforming, 155
- LC-MS, 19
- LC-MS/MS, 19
- LC-NMR, 19
- LDH, 416
- Lead (n):
 - compounds, 81, 191, 275
 - structures, 73–74, 80
- Lead:
 - decision process, 58
 - defined, 108, 213
 - discovery libraries, 135, 182
 - generation libraries, 136, 138
 - generation stage, 135
 - optimization, 136–137, 140, 148, 150–151, 234, 261–262, 267, 314
 - selection, 71
- Lectin/carbohydrate, posttranslational modifications, 244
- Lectins, 407
- Lederle Laboratories, 315
- Leprosy, 222
- Lercanidipine, 207
- Leucine, 361
- Leucocytes, destruction of, 397
- Leucocytosis, 408
- Leucopenia, 415–417
- Leucotoxicity, 413
- Leukemia, 419. *See also specific types of leukemia*
- Leukine, 30
- Leukocyte function-associated
 - antigen-1/intracellular adhesion molecules-1 (LFA/ICAM-1), 181
- Leukocytotoxicity, 413
- Levodopa, 202, discovery of, 217–219
- LHASA, Ltd., 66, 277
- LHRH antagonists, 226–227
- Library information management (LIMS), 41
- Life sciences research, 79–83
- Ligand(s):
 - based drug design, 21, 79
 - characterized, 58
 - endothiline ET_A receptors, 223
 - metal complex, 391
 - polymeric, 390, 400
 - potent and selective, 106
 - protein interactions and, 245
 - radiolabeled, 367, 369
- Lipid peroxidation (LPO), 414–415, 419
- Lipinski rules of five, 112–113, 134, 140, 234, 261, 384
- Lipophilicity, 138
- Lipopolyaccharides, 397
- Lipoprotein disorders, 202

- Liquid:
 chromatography, 264
 handling, 131, 142–143
 -liquid extraction, 145
 -phase combinatorial synthesis, 133–134
- Lisinopril, 125–127, 200
- Listeria monocytogenes* 408
- Lithium aluminum hydride, 190
- Liver:
 bile acid in, 393
 cirrhosis, 316–317
 drug distribution process, 113, 115
 dysfunction, 392
 enzyme monitoring, 202
 jaundice, 222
 metabolism, 114
 transporters in, 65
- Lixivaptan, 317, 319
- LocusLink, 270
- Losartan, 200–201
- Lovastatin, 202–203, 216
- Low-density lipoprotein cholesterol (LDLc), 389, 392
- Low-energy molecular conformation, 50–51
- Low-molecular-weight, 64
- LUDI, 140
- Lung cancer, 413
- Lungs, drug distribution, 114–115, 118
- Lymphokines, 408
- Lysine, 126
- Macrocylic:
 oligomeric amines, 386
 polyamines, 387
- Macrolactone, 4
- Macrolide, 4, 8–9
- MacroModel 6.5 modeling package, 50, 282
- Macromolecules, 105–106
- Macular degeneration, 10
- Magnetic resonance imaging (MRI), 367
- Malaria, 116
- Male erectile dysfunction, 217
- Maltose, 399
- Mammprint, 263
- Mmanagement strategies, in combinatorial chemistry:
 automated workflow, 146–148
 specifications, 146
- Man-made libraries, 79
- Mannitol, 414
- Manufacturing costs, 3. *See also* Economic considerations
- Mappicine, 178
- Map Viewer, 270
- Marijuana, 220
- Marinol, 220
- Marketing, 3, 136
- Mascot, 270
- Mass analyzer, in mass spectrometry analysis, 241
- Mass spectrometry (MS):
 applications, generally, 19, 241, 264
 combinatorial library screening, 133
 combinatorial library synthesis, 133, 145
 molecular conformation studies, 50, 52
- Mass-to-charge ratio (*m/z*), 241–242, 244
- Matrix-assisted laser desorption ionization (MALDI), 241, 264
- Matrix-assisted laser desorption ionization-mass spectrometry (MALDI-MS), 266
- Matrix-assisted laser desorption ionization time-of-flight (MALDI/TOF) analysis, 242
- Maximum tolerated dose (MTD), 235
- MDL:
 427, 170–171
 Information Systems, Inc., 276
 Toxicity Database, 66
- Mechloroethamine, 411
- Media:
 nuclear magnetic resonance (NMR), 49, 51
 parallel solution-phase synthesis, 172
- Medical Research Centre of Brookhaven National Laboratory, 219
- Medicinal chemistry:
 acronyms, 19, 22
 ADMET studies, 18, 27, 33, 36, 57–70, 84
 analog research, 199–209
 analytical techniques, 18–19, 27, 74–78
 applications, generally, 130, 303, 343–347
 chemoinformatics, 18
 contemporary, 103–128
 current status of, 26–27
 defined, 35–36
 drug design role, 23
 drug discovery and development process, 25, 35–41, 79–80, 84–85, 104, 109
 efficacy, pursuit of, 40–46, 84
 evolution of, 17–18
 as formalized discipline, 18–19, 23, 81–83
 future directions for, 19, 78–81
 historical perspectives, 23–26, 103–104
 intellectual property (IP), 18, 83–84
 knowledge vs. diversity paradox, 84–85
 metabolism, 341–342
 molecular conformation, 18, 23, 46–57
 nutraceuticals, 18
 overview of, 17–19
 process chemistry, 70–74
 roles of, immediate- and long-term, 36–40, 81–83
 site-directed mutagenesis examples, 27–28, 31
 synthetic chemistry, 18
 terminology, 19–21
 trends in, 31–35
- Medicinal chemists:
 continuing education, 82–83
 curriculum requirements, 82

- drug development process, 109, 112–115, 134
- formal training of, 23–24
- future directions for, 84–85
- graduate-level programs, 23–24
- roles of, generally, 81–82, 103
- Medicinal plants, 407
- MEGA (molecular evolutionary genetics analysis), 270
- Meisenheimer displacement, 178
- Melanoma, malignant, 413
- Melting point, 72
- Mepyramine, 298
- 2-Mercaptoethane sulfonate mesna, 411
- 2-Mercaptoethanesulfonic acid, 412
- Mercaptomethyl ketones, 182
- Merck & Co., 124, 151, 200, 203–204, 208–209
- Merck Index*, 10
- Mesna, 412
- Metabol Expert, 39, 276–277
- Metabolic pathways, 257
- Metabolic reaction, 275
- Metabolism:
 - in ADME, 18, 39
 - drug, 109, 114
 - protein interactions, 245
- Metabolism Database, 277
- Metabolite, 39, 276
- Metabophores, 21, 37, 63–65, 279
- Metal:
 - chelators, 390–392, 412
 - ions, 391
 - salts, 387
- Metastases, 152, 181, 372, 408
- Metathesis polymerization, 191
- METEOR, 277
- Metformin, 203
- (Meth)acrylamide, 394
- (Meth)acrylates, 394
- Methanol, 348–349
- Methanolysis, erythromycin studies, 7–8
- Methicillin-resistant *Staphylococcus aureus* (MRSA), 400
- Methotrexate, 105–106, 116, 410
- 3-Methoxytyramine, 218
- 3-Methoxy-4-hydroxyphenyl-acetic acid, 218
- Methyl:
 - α -phenylacetate, 64
 - benzoate, 64
 - ester, 349
 - groups, 124, 356–357
 - propionate, 63, 343
- Methylation, 7, 265
- Methyldopa, 203
- Methylene groups, 105, 124
- Methyl 4-phenylbutyrate, 64
- Methylhistamine, 300, 307
- Methylthioiminium salts, 174
- Methyl 3-arylpropionate system, 63
- Methyl 3-phenylpropionate, 63
- Metiamide, 219–220, 307–309
- Metoclopramide, 204
- Metoprolol, 208
- Metronidazole, 398
- Mevastain, 202
- Mevinolin, 214
- Mibefradil, 215
- Michael addition, 349
- Miconazole, 206
- Microarray(s):
 - analysis, 238
 - DNA, 250
 - gene expression, 254–255
 - protein, 248, 250–253, 262–263
 - technologies, 71
- Microcalorimetry, 19, 27–28, 52
- Microdosing, 374
- Microengineering, 41
- Microfluidic devices, 155
- Microreactors, 133, 143
- Microtiter plates (MTPs), 131, 143–145
- Microwave-assisted parallel synthesis (MAPS), 178
- Microwave synthesizers, 142
- Midazolam, 350
- Migraines, 202, 314
- Mikania cordata*, 417
- Millennium Pharmaceuticals, 315
- Mimotope SynPhase system, 143
- Minaprine, 224–225
- Miniaturization, 154–155
- Minimum laboratory concentrations (MICs), 7–8
- Mistletoe lectin, 407–408
- Mitomycin C, 413
- Mitsunobu reagent, 188
- Mix-and-sort synthesis, 142–143
- Mix-and-sort systems, combinatorial libraries, 143
- Mix-and-split process, 132
- MKH-57, 174
- MLS_B resistance, 182
- MNDO calculations, 21
- MOBY, 48, 281
- Moexipril, 127
- Mofarotene, 409, 411
- Molar ratio, 61
- Molecular, generally:
 - conformation, *see* Molecular conformation
 - diversity, 45–46, 80, 84–85
 - imaging, 257
 - mechanics, 21
 - modeling, *see* Molecular modeling
 - orbital calculations, 20–21
 - oxygen, 389
 - scaffold systems, 43, 80, 84, 137, 152
 - sequestrants, polymeric 384
 - weight, significance of, 119, 124, 133, 138–139
- Molecular biology, 26, 33, 310, 313

- Molecular Biology, 39
- Molecular conformation:
- ACE inhibition, 123
 - assessment and handling of, 46–57
 - implications of, 18, 23
 - similarity-dissimilarity indices, 57
- Molecular diversity, drug efficacy research, 45–46
- Molecular modeling:
- applications, 4, 76
 - 3D, 47–48, 280–281
- Molecular Simulations, 48, 281
- Molecular Toxicology Platform (Phase-1), 66
- Monoamine-oxidase aldehyde-dehydrogenase, 218
- Monoamine oxidases (MAOs), 371
- Monoclonal antibodies, 30, 252, 367
- MOPAC, 47
- Morphinanes, 216
- Morphine, 216
- Morpholine, 225
- Mosapride, 204–205
- Motif, defined, 244
- Mouse studies, 249, 356, 370, 409–418
- Mozavaptan, 317, 319
- mRNA expression, 238
- Mucomyst, 411
- Multiagent, 39
- MULTICASE, 66
- Multicase, Inc., 276
- Multicomponent:
- reactions, 177–178
 - synergies, 62–63
- Multiconformational assessment, 50
- Multidrug exporter, 111
- Multidrug resistance (MDR), 42–45, 59, 69, 83, 151
- Multipins, 131–132
- Multiple interactions, 60
- Multiple sclerosis, 10, 30, 369
- Multiple sequence alignment (MSA), 270
- Multistep drug synthesis, 134, 144
- Multivalent:
- drug strategies, 39
 - ligands, 21
 - strategies, 79
- Murine leukemia virus, 356
- Murine xenograft models, 370
- Muscarine, 296
- Muscarinic M1 agonist, 224
- Muscarinic receptors, 296, 368
- Muscle relaxation, 340
- Mutagenesis, site-directed, *see* Site-directed mutagenesis (SDM)
- Mutagenicity, 108–109
- Mutations, 108
- Myeloprotection, 416
- Myelosuppression, 412–413
- Myocardial function, 29, 385
- MyoScint, 30
- NAD synthetase inhibitors, 180
- Nanomolar affinities, 225
- Nanotechnology, 58, 65, 79
- Nano Vision, 48, 281
- Naratriptan, 204
- Naringenin chalcone, 46
- National Institute for Environmental Health Science (NIEHS), 66
- National Institute for Occupational Safety and Health (NIOSH), Information Division, 66
- National Institute of Neurological Diseases and Strokes, 314
- National Institutes of Health (NIH), 314
- Natural iron chelators, 391
- Natural killer (NK) cells, 408
- Natural product(s):
- characterized, 39, 191
 - libraries, 26
 - parallel solid-phase synthesis (PSPS), 186
 - scaffolds, 191
 - synthesis, 134
- Nature*, 131
- NCBI Entrez, 269
- Negative SAR, 41–42, 63–64
- Nemesis, 48, 281
- Neonates:
- esterase capability, 65
 - neonatal metabolic capabilities, 275
- Neoplastic transformation, 416
- Nephrotoxicity, 220, 411–413
- Nervous systems, 407. *See also specific nervous systems*
- Neumega, 30
- Neupogen, 30
- Neural networks, 139
- Neurodegenerative diseases/disorders, 182, 368–369
- Neuroendocrine:
- immune system, 407
 - tumors, 181
- Neurohormones, 218
- Neurokinin -1 (NK-1), 180
- Neurokinin (NK) receptor antagonists, 183
- Neuroleptics, 214–215, 221, 375
- Neurological function, 385
- Neurologic toxicity, 413
- Neuromodulators, 407
- Neuroregulators, 407
- Neurotoxicity, 412–413
- Neurotransmitters, 315, 369, 407
- Neutral SAR, 41–42, 63–64
- Neutropenia, 413
- Neutropin, 29
- Nevirapine
- characterized, 354–355
 - chemical development and process research, 357–360
 - chemical structure, 354

- clinical studies, 361–362
- lead discovery, 355–357
- lead optimization, 356–357
- mechanism of action, 360–361
- medicinal chemistry approach, 360
- New activity, emergence of, *see* Emergent activity
- New chemical entities (NCEs):
 - defined, 24
 - drug discovery and development process, 25–26, 61, 81, 84
 - patents, 33
 - production of, 55
- New drug discovery paradigm, 41, 45, 58
- Nicotinamide adenine dinucleotide, 417
- Nicotine, 296
- Nicotinic receptors, 296
- Nifedipine, 206
- 96-well, generally:
 - arrays, 262
 - filter apparatus, 154
 - microplates, 20, 143, 169, 260
 - MTPs, 155
- Nitric oxide, 116
- Nitriles, 187
- Nitrite oxide, 369
- 2-Nitroanilines, 178
- Nitrobenzamides, 322
- 2-Nitrobenzoyl chloride, 171–172
- Nitrogen/nitrogen group, 7, 71, 310, 349, 367
- Nitroglycerine, 116
- Nitroguanidines, 304, 308
- Nitroxides, 107
- Nizatidine, 310
- Non-Hodgkin's lymphoma, 30
- Nonnucleoside reverse transcriptase inhibitor (NNRTI), 362
- Non-small cell lung cancer, 413
- Noradrenaline, 218, 296
- Norditropin, 29
- Norepinephrine, 313, 371
- Notebook entries, 170
- Novartis, 30, 201, 203, 208–209, 215–216, 265
- Novelty, analog design, 215
- Novolin/Novolin L/Novolin R, 29
- Novo Nordisk, 29
- Nuclear imaging, *see* Nuclear magnetic resonance (NMR) applications
 - clinical studies, 373–376
 - drug development process and challenges of, 365–366
 - future directions for, 376–377
 - positron emission tomography (PET), 366–368
 - role in drug discovery, 368–376
 - technology, principles and evolution of, 366–368
- Nuclear magnetic resonance (NMR) applications:
 - characterized, 2, 19, 246
 - combinatorial library synthesis, 145
 - drug metabolism studies, 282–284
 - erythromycin, 5, 10
 - molecular conformation assessment, 47, 49–55
 - spectroscopy, 170
- Nucleophiles, 140, 185, 187, 191
- Nucleophilic attack, 34
- Nucleotide libraries, 24
- Nutraceuticals, 18, 21
- Observational studies, COX-2 inhibitors, 13
- Ochratoxin-A, 416
- Ocimum sanctum*, 417
- Octapeptide(s), angiotensin II, 117–119
- Olefinic monomers, 400
- Olefins, 186, 399
- Oligomers, ROMP, 191
- Oligonucleosides, 130
- Oligonucleotide(s):
 - characterized, 252
 - compound libraries, 28
 - solid-phase synthesis, 131
- Oligopeptides, 130
- Oligosaccharide(s):
 - characterized, 130
 - receptors, 399
 - synthesis, 143
- Omeprazole, 200–201
- 3-O-methyl-L-dopa, 218
- OMIM, 270
- OncoScint, 30
- One-bead, one-peptide approach, 132
- OPC-41061, 317
- OPC-31260, 316–317
- OPC-21268, 317
- Open reading frames (ORFs), 245–246, 250–251
- Opioid(s):
 - analgesics, 341–344, 350
 - anesthetic agents, 350
 - ORL1 receptor agonists, 213
- Optimization library, 138. *See also* Lead, optimization
- Oral absorption, 112–113, 124
- Oral administration:
 - ADMET studies, 57–58
 - DOPA, 219
 - implications of, 107, 110–112
 - Lipinski rules of five, 112–113
- Oral bioavailability, 227
- Oral uptake, 113
- Organ:
 - damage, 390
 - distribution, 114–115
- Organic:
 - chemistry, 23, 81–82, 149
 - compounds, 28, 190
 - synthesis, multistep, 148
- Orphan diseases, 228

- Ortho Biotech, 29–30
 Orthoclone, 30
 Orthoesters, 172
 Ortho-McNeil, 29
 Osmolarity, 317
 Osmotic balance, 316
 Osteoporosis, 10, 182, 207
 Ovarian carcinoma, 413
 Overexpression, 259, 261, 265
 Oxadizoles, 170
 Oxalic acid salt, 344
 Oxazinobenzodiazepines, 324–332
 Oxazoles, 182
 Oxetane, molecular conformation study, 53, 57
 Oxford Molecular, 48, 281
 Oxiconazole, 206
 Oxidation, 107, 114, 186, 243
 Oxidative hydroxylation, 114
 4-(1,3,4-Oxadiazol-2-yl)-*N,N*-dialkylbenzenesulfonamides, 170
 Oxyacid anions, 302
 Oxyanions, 391
 Oxygen:
 characterized, 118, 124, 367
 free radicals, 414
 Oxytocin receptor, 318

 Paclitaxel (PAC), 42–43, 52, 59, 68–69, 82–83, 414
 Paget's disease, 208
 Palladium cross-coupling, 176
 Palliative treatment, 41, 79
 Pamidronate disodium, 208–209
Panax ginseng, 408
 Pantoprazole, 200–201
Para-aminobenzoate, 106
 Parallel array chemistry, 139
 Parallel chemistry, 213–214
 Parallel solution-phase synthesis (PSPS):
 catalysts, 178, 184–185, 190–191
 future directions for, 191
 historical perspectives, 169–172
 implications of, 154
 recent reports, 172–178
 scavengers, 178, 184–185, 190–191
 semiautomated, 191
 solid reagents, 178, 184–185, 190–191
 Parallel synthesis, generally, 133–134, 150, 300, 314
 Paralysis, 397
 Parasympathetic nervous system, 297
 Paresthesias, 385
 Parkinson's disease, 218–219, 371
 Paromomycin, 401
 PAR-1, 315
 Partition coefficients, 57
 Partitioning, bin-based, 139
 PAS, 203
 Passerini reaction, 177

 Passive cutaneous anaphylaxis (PCA), 171
 Passive diffusion, 111–112, 114
 Patentability, 109, 227. *See also* Patents
 Patent Cooperation Treaty, 9
 Patents:
 ACE inhibitors, 200
 β_1 -adrenergic blocking agents, 208
 angiotensin II antagonists, 201
 antimigraine drugs, 204
 application, submission of, 38
 azatadine analogs, 205
 azithromycin, 9–10
 calcium channel blockers, 207
 claims, 83–84
 clodronate analogs, 209
 gastroprokinetic drugs, 204
 glitazones, 202
 miconazole analogs, 206
 omeprazole and analogs, 201
 prazosin, 13
 statins, 203
 suitable lead substance, 104
 trends in, 19
 Pathology, 128
 Pathophysiology, 18, 28, 38, 79
 PBEMP, 187
 PC Model, 48, 281
 PDB 271
 PDBsum, 271
 PDE III inhibitors, 77
 PDE4 activity, 369, 372
 PE Biosystems, 24
 Pediatrics:
 growth hormone deficiency, 29
 HIV, 29
 Penicillins, 222
 Pentapeptides, synthesis of, 131
 Pepsin, 296
 Pepstatin/cathepsin D complex, 140
 Peptic ulcer disease, 296–297, 299
 Peptide(s):
 antimicrobial, 400
 bonds, 118, 120
 characterized, 173
 chemistry, 132, 134
 chronic oral administration and, 120
 coupling, 185
 drug development example, 120
 hydrolysis, 152
 libraries, 24, 28
 mass fingerprinting, 242
 parenteral lead, 128
 phytoalexin studies, 45
 pit viper-inspired, 120
 sequencing, 255
 synthesis, 131, 250
 therapeutic, 368

- PeptIdent, 270
 Peptidomimetic pyrazinone antithrombotics, 184
 Peptidomimetics, 120–121, 128
 Peptidyl-prolyl isomerase (PPIase), 180
 Perhydro-3-oxo-1,4-diazepinium derivatives, 188
 Perindopril, 127
 Peritoneal macrophages, 409
 Peroxidative tissue, 390
 Peroxisome proliferator-activated receptor gamma (PPAR- γ), 202
 Pertussis, 416
 Peterson, Per, Dr., 315
 PFAM, 271
 Pfizer (Groton, CT):
 azithromycin, 9–10
 drug discovery/development, 203–204, 206–207, 217
 partnership with Pliva, 15
 prazosin, 13
 pH:
 chemoprotectant agents and, 411
 efficacy studies, 111
 molecular conformation assessment, 51
 phosphate binding and, 387–388
 Phage display, posttranslational modifications, 246
 Phagocytosis, 409
 Pharmaceutical industry, 23–24
 Pharmaceutical properties, 115
 Pharmacia & Upjohn, 29
 Pharmacodynamics, 110, 374, 419
 Pharmacogenetics, 21, 28, 40–41, 65, 79, 278
 Pharmacogenomic profile, 373
 Pharmacogenomics, 265
 Pharmacokinetic(s):
 antimigraine drugs, 202
 deficiencies, 107
 defined, 110
 endotheline ET_A receptors, 223
 modeling methods, 278–279, 287
 nevirapine studies, 361
 nifedipine analogs, 207
 proton pump inhibitors, 200
 remifentanyl, 349–350
 significance of, 25, 150, 419
 Pharmacological:
 profile, 59–61
 proof of principle, 28
 prototype, 28
 receptors, 296
 Pharmacology, 235, 262–263
 Pharmacophore(s):
 combinatorial library design, 138
 defined, 106
 efficacy-related, 68–69
 functions of, 21, 37, 55, 63–64, 67, 80, 138, 317
 model, 141
 Phase-I, 66
 Phase II/Phase III trials, 235–236
 Phenanthroline, 391
 1,2-Phenethyl diamines, 182
 Phenothiazine, 221
 Phenprocoumon, 226
 Phenprocoumon K1, 226
 Phenyl:
 esters, 176
 groups, 72
 Phenylalanine, 46
 Phenylbutazone, 417
 2-Phenylglycerol, 52–53
 4-Phenyl-2*H*-phthalazin-1-one, 187
 Phenylhydrazines, 174, 177
 Phenylpiperidines, 216
 Phenytoin, 275
 Phosphate:
 anions, 389–390
 binder therapy, 386
 binding, 387–388
 Phosphatidylinositol-4-phosphate phosphatase, 27, 32
 Phosphodiesterases, 75–78, 227
 Phosphodiesterase type 5 (PDE5) inhibitor, 217
 Phospholipids, 400
 Phosphorylation, 243
 Photoaffinity labeling studies, 28
 Photolabile protecting groups, 131
 Photolithography, 131, 155, 250
 Physical organic chemistry, 82, 309, 387
 Physical organic principles, 81–83
Physicians' Desk Reference, 10, 12
 Physicochemical properties, 57–58, 284
 Physiopathological hypotheses:
 H₂-receptor antagonists, 219–220
 levodopa, 217–219
 rimonabant, 220–221
 Phytoalexins, 45–46
 Phytochemical(s):
 implications of, 409
 pathways, 45–46
 structures, 45
Picrorhiza kurroa, 417
 Pioglitazone, 202
 Piperazine, 150
 Piperidine, 343, 349
 Pipetting, 144
 Pirenzepine, 355
 p*K_a* value, 57, 111
 PK data, 28
 Plant(s):
 extracts, 406
 molecular diversity enhancement study, 45
 Plasma protein binding factors, 45
 Plastic, 155
 Platelet aggregation, 179
 Platelet-derived growth hormone, 29

- Platinum compounds, 413
- Plicamine, 186
- PM5VTHT, 187
- PNU-96–988, 226
- Polar surface area, 191
- Poly(ADP-ribose), 32
- Poly(ADP-ribose)glycohydrolase (PARG), 27–28
- Polyanions, 398–399
- Polyclonal antibodies, 252
- Polydentate chelate effect, 388
- Polyethers, 394
- Polyethylene glycol monomethyl ether, 134
- Polyethylene rods, 131
- Polyhydroxamic acid polymers, 392
- Polymer/polymeric:
- amines, 392
 - anti-infective agents, 396–397
 - antimicrobial agents, 400–401
 - architecture of, 397
 - characterized, 383–384, 401
 - chronic renal failure and, 386–389
 - cholesterol-lowering agents, 392–396
 - functional, 383, 401
 - future research directions, 401
 - hyperkalemia, 385–386
 - inorganic ions in GI tract, 385
 - iron overload disorders, 389–392
 - physicochemical properties of, 401
 - as specific molecular sequestrants, 384
 - toxin sequestration, 397–400
- Polymerase chain reaction (PCR), 132, 250
- Polymorphism, 228
- Polypropylene mesh resin packets, 131
- Polystyrene beads, cross-linked, 131
- Polystyrenes, 398–399
- Polyvalent interactions/polyvalency, 384, 396–397, 400–401
- Pooling, 131–133
- Pool/split, 131
- Portion/mix, 131
- Positional scanning, 132
- Positive SAR, 41–42
- Positron emission tomography (PET):
- applications, generally, 365, 366–368
 - clinical studies, 373–374
 - preclinical studies, 371–373
 - principles of, 366–367
- Positron-emitting radionuclides, 367
- Postsynthesis processing, combinatorial libraries, 144–146
- Posttranslational modifications (PTMs), 238–239, 241, 243–245, 257, 259, 264
- Potassium:
- characterized, 385–386
 - hydroxide, 176
 - polymers, 385–386
 - salt, 344
- Potency:
- analog design, 215
 - combinatorial libraries, 134
 - defined, 110
 - hypertension drugs and, 125–127
 - level of, 109
 - significance of, 104–108
- Practolol, 207
- Pravastatin, 202–203, 216
- Prazosin, 13–15
- Preclinical:
- development compound, 25
 - testing paradigm, 79
- PredictProtein, 247, 270
- Pregnancy, 222
- Prenylflavanoid Diels-Alder natural products, 188
- Prescriptions, physician authority, 13
- Prestwick Chemical Library, 223
- Preventive paradigms, 79
- Prey, posttranslational modifications, 245–246
- Primary structure, defined, 243
- Principle component analysis (PCA), 137
- Prion infections, 222
- Private-sector drug discovery program, 23
- Privileged structures, 21, 141
- Process chemistry:
- characterized, 18
 - cost and green chemistry, 70–71
 - stereochemistry defined, 71–74
- Procrit, 29
- Procter & Gamble, 209
- Prodrug strategies, 21, 39, 59–60, 68, 79–80, 124, 202, 218
- Product(s):
- diversity, 139
 - evaluation, 139
 - purification, 144–145
- Production costs, 70–71
- Production-scale synthesis, combinatorial chemistry, 136
- Profiling data, 41, 59–61, 67, 70, 79, 136
- Profit incentives, 3
- Progenitor cells, 413
- Proleukin, 30
- Proline:
- ACE inhibition, 123
 - derivatives, 180
- Promethazine, 221
- Proof-of-concept, 249
- Proof-of-principle experiments, 176–177
- Prophylactic treatment paradigms, 79
- Propionic anhydrides, 344, 348
- Propofol, 339, 350
- Propranolol, 207–208
- Proprietary rights, 115
- ProSite, 271
- Prostaglandins, 222, 409

- Prostascint, 30
- Prostate cancer, 176, 373
- Protease:
 - characterized, 137, 141
 - inhibitors, 361, 401
- Protection-deprotection scheme, 7
- Protein(s):
 - ATP-dependent, 183
 - expression profiling, 252, 264
 - fold/folding, 75–78, 254, 271
 - identification, 242, 255
 - interactions, 238, 245
 - localization of, 238
 - microarrays, 248, 250–251, 253, 262–263
 - production of, 45
 - quantitation, software and databases, 255
 - receptors, 111
 - signatures, 252, 257
 - structure, *see* Protein structure
 - synthesis, 417
- Protein capture arrays:
 - advantages of, 252
 - disadvantages of, 253
 - implementations of, 251–252
 - underlying principles, 251
- Protein capture chips, 249
- Protein chip technology:
 - current state of, 249–253, 264
 - functional protein microarrays, 248, 250–251
 - posttranslational modifications, 246
 - protein capture microarrays, 248, 251–253
- Protein Data Bank, 47
- Protein Design Labs, 30
- Protein-ligand structures, 261
- Protein-lipid interactions, 238
- Protein-nucleotide interaction, 239
- Protein-phospholipid interaction assays, 258
- Protein-protein interactions (PPI)s, 239, 245, 255, 368
- Protein structure:
 - analysis, 246–248
 - computational determination, 247
 - laboratory determination, 246
 - significance of, 243, 313
- Protein tyrosine phosphatase 1B (PPT1 B) inhibitors, 180
- Proteolysis, 243
- Proteome-wide protein-ligand study, 245
- Proteomic data analysis:
 - computational infrastructure, 254
 - database management, 254–255
 - data checking and manipulation, 254–255
 - data generation, 253
 - LIMS, 254
 - software, 255
 - storage, 253–254
- Proteomics:
 - characterized, 18, 21, 26, 28, 33–34, 38–39, 58, 67, 77, 79, 83, 261, 313, 401
 - data analysis, 253–256
 - fractionation, 239–240
 - functional areas of, 239, 249
 - identification, 240–242, 248
 - protein chip technology, 248–253
 - purification, 239–240
 - quantitation, 242, 248, 265
 - research goals, 238–239
- ProtoMetrix, 249
- Proton pump:
 - functions of, 200
 - inhibitors, 200, 310
- Prototypes, 28
- Protropin, 29
- ProtScale, 247, 271
- Psychiatric disorders, 367
- Public policy, 80
- PubMed, 270
- Pulmonary:
 - embolism, 29
 - toxicity, 413
- Pulmozyme, 29
- Purification:
 - applicaitons, generally, 182, 239, 251
 - high-throughput techniques, 149
 - of nevirapine, 360
 - parallel solution-phase synthesis (PSPS), 185, 191
 - process characterized, 60
 - tandem affinity, 259
- Purines, 183
- Pyrazinobenzodiazepines, 324–332
- Pyrazinones, 184
- Pyrazoles, 221
- Pyrazolines, 174, 177, 186, 221
- Pyridazine, 170
- Pyridaziny rings, 225
- Pyridines, 175–176, 310, 357–358
- Pyridinium bromide hydrobromide, 175
- Pyridobenzyo substance, 356
- Pyrimidines, 174
- Pyrimidinones, 172
- Pyrrolidines, 181
- Pyrrolidinyl, 170
- Quadrupole analyzer, 341
- Quality of life, 79–80, 408
- Quantitation, 239
- Quantitative structure-activity relationships (QSARs), 261, 284
- Quantitative structure-property relationship (QSPR), 141
- Quantitative structure-toxicity relationship (QSTR), 262
- Quantum mechanics, 21, 47

- Quartz, 155
 Quaternary amines, 388
 Quaternary structure, defined, 243
 Quinacrine, 222
 Quinapril, 127
 Quinazolinones, 171
 Quinidine, 116
- Rabeprazole, 201
 Racemic, 72–73
 Racemic dihydroxyphenylalanine, 219
 Racemization, 172
 Raclopride, 375
 Radiation, chemoprotectants, *see* Radioprotection
 RADICAL (Registration, Analysis and Design Interface for Combinatorial Libraries), 146–147, 149
 Radio-frequency (RF) tag, 143
 Radiolabeled probes, 367
 Radioprotection:
 antitumor agents, 418–419
 from botanicals, 418
 components of, 417–418
 Ramipril, 127
 Random walk, 49, 59
 Raney nickel, 178
 Ranitidine, 219–220
 Rasayana:
 botanicals, 408–409
 characterized, 407
 Rational drug design, 23–24
 Rationally design molecules, 39
 Rat studies, 226, 330–332, 342–343
 Razoxane, 376
 Reaction workup, 142, 144–145
 Reactor blocks, 142
 Reagent(s):
 diversity, 139
 research, 71
 screening combinatorial libraries, 131–132
 solid-supported (SSRs), 178
 RECAP technique, 141
 Receptor/ligand tag, posttranslational modifications, 245
 Rechlorination, 358–359
 Recognition site, 246
 Recombinate, 29
 Recombine, 131
 Recordati, 206–207
 Recorder, in mass spectrometry analysis, 241
 Recrystallization, 72
 Rectome, 271
 Red blood cells, 58
 Reduction, parallel solid-phase synthesis (PSPS), 186
 Reductive alkylation methods, 72
 Regiospecific monodisplacement reaction, 170
 Regranex, 29
- Relational databases, 37
 Relcovaptan, 317
 Remifentanyl:
 chemical development of, 344–349
 discovery of, 340–344
 human clinical trials, 349–350
 manufacturing route, 347–348
 medicinal chemistry route, 341–342, 348–349
 Renagel, 389
 Renal:
 dopamine receptors, 75–78
 failure, 29, 316
 impairment, 385. *See also* Chronic renal failure
 toxicity, 413
 Renin, inhibition of, 119
 Renin-angiotensin-aldosterone system, 117–119, 123, 128
 ReoPro, 30
 RepeatMasker, 269
 Reperfusion injury, 181
 Research and development (R&D) costs, 3
 Resin-bound reagents, 178
 Resistant virus, 361
 Respiratory failure, 385
 Respiratory syncytial virus disease, 30
 Retesting, 260
 Retevase, 29
 Retinitis, 30
 Retinoids, 409
 Retroviruses, 355
 Rexinoids, 409
 Rhinitis, allergic, 314
 Rhodacyanine dyes, antimalarial, 174
 Rhodamines, 174
 Rimonabant, obesity and, 220–221
 Risedronate sodium, 208–209
 Risk assessment, 28, 66
 Risperidone, 370
 Rituxan, 30
 Rivastigmine, 371
 Rizatriptan, 202, 204
 RNA:
 functions of, 105
 interference (RNAi), 259, 261
 polymerase, 246
 synthesis, 419
 Robbins Scientific, 24
 Robots/robotics, 144, 146–147, 149, 213, 253, 355
 Robustness, 133
 Roche, 208–209, 215
 Rodent studies, 220
 Roferon-A, 30
 Rolipram, 369
 ROMP (ring-opening metathesis polymerization)
 agents, 189, 191
 Rosetta, 247, 271
 Rosiglitazone, 202
 Rosuvastatin, 216

- Rotamase, 180
- Rotatable bonds, 138, 191
- Roxatidine, 219–220
- Rule of five, 58, 134, 140
- Rule of threes, 113
- RWJ-56423, 314
- RWJ-53308, 314
- RWJ-355871, 314

- Sac 1 p, 27, 32
- Safety:
 - analog design, 215
 - bioavailability and, 226–227
- Saizen, 29
- Salmeterol, 186
- Salmonella enteritidis*, 397
- Salt(s):
 - ammonium, 344, 394
 - calcium, 386
 - concentration, blood pressure regulation, 117–119
 - characterized, 228
 - guanidinium, 386–387
 - iminium, 174
 - metal, 387
 - oxalic acid, 344
 - potassium, 344
 - sodium, 344, 398–399
 - tosylated, 174, 328
- Sample inlet, in mass spectrometry analysis, 241
- Sample production, 2
- Sandoz, 10, 203, 208
- Sandwich ELISA, 252–253
- Sankyo, 202–203
- SanofiAventis, 220
- Sanofi-Synthélabo, 201, 209, 317
- Saponins, 415–416, 419
- Sarcodictine, 178
- Sarcoma-180, 413
- Saturation kinetics, 369
- Scaffold hopping/morphing, 215–216
- Scale, in emergent technologies, 237
- Scale-up issues, 2–3
- Scavengers, solid-supported (SSSs), 178
- Schering-Plough, 30, 205
- Schild plot, 296, 298–299
- Schizophrenia, 369, 376
- Schrödinger equation, 21
- Scientific/primary news journals, 19
- SciFinder*, 10–11
- SciVision, 66
- Screening libraries, 260
- Secondary amines, 72, 388
- Secondary antibodies, 252
- Secondary structure:
 - defined, 243
 - structure prediction, 247
- Secretagogogs, 297–298
- Sedatives, 205, 222
- Selectin inhibitors, 181
- Selective uptake mechanisms, 112
- Selectivity, significance of, 104–107, 109, 134, 136, 215, 369, 383
- Selenium, 409
- SELEX procedures, 252
- Semecarpus anacardium*, 419
- Semiempirical calculations, 21
- Sepracor, 205
- Septic shock, 397
- Sequence:
 - analysis, 257
 - homologs, 244
 - homology, 255
- Serena Software, 48, 281
- Serine protease inhibitors, 314
- Sermorelin, 29
- Serono Labs, 29
- Serostim, 29
- Serotonin, 369, 371
- Sertraconazole, 206
- Serum protein binding, 114
- Sexual dysfunction, 217
- Shatavarins, 416
- Sickle cell anemia, 390
- Side effects, significance of, 3, 6, 124, 221, 235, 265, 350, 397
- Siderophores desferrioxamine, 391
- Siegfried, 206
- Signal transduction, 245, 257, 369–370
- Sildenafil, 217
- Silico screening, 37
- Silicon, 155
- Silicon Graphics Indigo 2 workstation, 50
- Simian immunodeficiency virus (SIV), 356
- Similarity-dissimilarity indices, 57–58
- Simulect, 30
- Simvastatin, 202–203
- Single-molecular systems, 79
- Single nucleotide polymorphisms (SNPs), 21, 40, 265
- Single photon emission tomography (SPECT), 366
- Site-directed mutagenesis (SDM):
 - characterized, 27–31, 36
 - compound libraries and, 45
 - future directions for, 78
 - historical perspectives, 39
- Sitoinoside VII/VIII, 415
- 6–31G*, 20, 51
- 6–32G*, 282
- SKF 97426-A, 394
- SKF-101926, 317
- SKF-105494, 317
- Skin discoloration, 221
- Sleep disturbance, 370
- Slurries, solid-phase synthesis, 134
- SLV 319, 220–221
- Small interfering RNAs (siRNA), 259, 266
- Small intestine, 111

- Small-molecular combinatorial chemistry, 24
- Small-molecule:
- compounds, 83
 - drug discovery and development, 27–28, 33–35
 - synthesis, 132–133, 135
- Small ring system, 52–54
- SMART (single or multiple addressable radio-frequency tag) semiconductor, 133
- SmithKline & French Research Institute, 295, 305, 317, 394
- SmithKline Beecham, 150, 201–202, 204
- Snake venom, 117, 119–120, 123
- SNP Consortium, 66
- Société d'Études Scientifiques et Industrielles de l'Île-de-France, 204
- Sodium:
- channel blockers, 179
 - hydride, 357, 360
 - polystyrene sulfonate, 385–386
 - salt, 344, 398–399
 - sulfonate, 411
 - thiosulfate (STS), 411–412
- Soft donor atoms, 391
- Soft drugs, 21, 39, 60, 63–65, 71, 79–80, 342
- Soft tissue calcification, 386
- Solid-phase:
- beads, 131–132
 - chemistry, 131–135, 149
 - extraction (SPE), 145
 - peptide chemistry, 143–144
 - synthesis, 145, 152
- Solids, delivery of, 142
- Solid-state interactions, 49
- Solid-supported catalysts (SSCs), 178
- Solid-supported reagents (SSRs), 178
- Solid-supported scavengers (SSSs), 178
- Solid tumor cancer cells, 263
- Solubility, 108, 191, 227
- Soluble mixture libraries, 135
- Solution chemistry, 144
- Solution-phase, *see* Parallel solution-phase synthesis
- combinatorial chemistry, 134, 152
 - synthesis, 153
- Solution synthesis, 183
- Solvay Pharmaceuticals, 221
- Somatostatin:
- antagonists, 181
 - characterized, 150–151
- SOSA (selective optimization of side activities) approach:
- characterized, 214, 223, 226–228
 - examples of, 223–226
 - rationale for, 223
- Sour Pliva (Zagreb):
- azithromycin, 9–10
 - Pfizer partnership, 15
- Soybean cyst nematode infection, 45–46
- Specification, combinatorial library design, 138
- Specificity, 369
- Spectroscopy applications, 39. *See also* Mass spectrometry
- Speed, in emergent technologies, 237
- Spiroindolinones, 317
- Spiropyrrrolopyrroles, 183
- Spir[pyrrolidine-2,3N-oxindole] libraries, 173
- Split-and-mix:
- philosophy, 133–134, 139
 - synthesis, 131, 155
- Split-split synthesis, 144
- Springer-Verlag, 48, 281
- Squibb, 120, 124, 200
- SR 141716A, 220
- SR-121463, 317
- SSR-4-149415, 317
- Stability, drug development process, 109
- Staphylococcus aureus*, 397, 400
- STAR, 66
- State of nonspecifically increased resistance of an organism (SNIR), 407
- Statins, 10, 202, 222, 392, 396
- Statistical analysis, 255
- Staudinger protocol, 190
- Stem cell proliferation, 415
- Stereochemistry, 10, 71–74, 107, 121, 307
- Stereocontrol, 71
- Steric environment, 72
- Steric physicochemical properties, 64
- Steroid/steroidal:
- analogs, 216
 - characterized, 222
 - hormones, 214
 - lactones, 415
 - saponins, 416
- Stimulant effect, 303
- Stipiamide, 178
- Stirring blocks, 142
- Stoichiometry, 83
- Storage access network (SAN), 253–254
- Strecker reaction, 344
- Strokes, 29, 116, 392
- Structural-absorption relationships (SABRs), 58, 65
- Structural analogs, 214
- Structural database, 54
- Structural proteomics, 261
- Structure metabolism relationships (SMRs), 279
- Structure stereochemical relationship (SSR), 73
- Structure-activity analysis, 295, 301, 305–306, 317. *See also* Dynamic structure-activity analysis (DSAA)

- Structure-activity relationships (SARs):
 captopril analogs, 122–124
 checking and manipulation, 254–255
 classical studies, 27, 31, 75
 combinatorial chemistry, 136, 151–152
 combinatorial library design, 140
 directing distribution and, 58
 efficacy-related, 41–42, 58
 establishment of, 121
 future research directions, 39
 during HTS, 41–42, 81
 models of, 23
 molecular conformation studies, 52
 multidrug resistance (MDR) and, 42, 83
 negative, 41–42, 63–64
 neutral, 41–42, 63–64
 nevirapine, 356–358
 paclitaxel (PAC), 42–43, 69
 polymeric amines, 388–389
 positive, 41–42
 reverse, 28
 selectivity-related, 65
 significance of, 23, 80, 309
 site-directed mutagenesis (SDM), 31
 small-molecule drug design, 27, 58–59
 suitable lead substance, 107
 toxicology, 67–68
 ultrashort-acting analgesics, 343–344
- Structure-based drug design, 21, 33, 35, 106, 314
- Structure-debenzylation relationship (SDeBR), 73
- Structure-distribution relationship (SDR), 58–59, 65
- Structure-elimination relationships (SERs), 65
- Structure-function relationships, 246–248
- Structure-metabolism relationship (SMR), 63–65, 68, 286
- Structure-toxicity relationship (STR), 67
- Styrene, 394
- 3-Substituted indoles, 180
- Succinylcholine, 340
- Sufentanil, 341, 343
- Suitable lead substance, characteristics of:
 analog attrition, 108
 overview, 104–105
 potency, 104–107
 selectivity, 104–107
 structure-activity relationships (SARs), 107
 toxicity, 107–108
- Sulconazole, 206
- Sulfamides, 221
- Sulfate, 114
- Sulfathiazole, 223–224
- Sulfenamide, 200
- Sulfhydryl groups, 121–122, 124
- Sulfhydryl/sulfide-containing tissue, 107
- Sulfisoxazole, 223–224
- Sulfonamides, 189, 222
- Sulfonic acid groups, 398
- Sulfonyl chlorides, 191
- Sulfur:
 characterized, 124
 electron-withdrawing, 220
 methylene isosterism, 306–307
- Sumatriptan, 202, 204
- Supercritical fluid chromatography (SFC), 245
- Supermolecule, formation process, 105
- Superoxide dismutase, 414
- Superoxide radicals, 415
- Suppliers, of combinatorial systems and compound library trends, 24
- Surface-enhanced laser desorption ionization (SELDI), 264
- Surface plasmon resonance, 19
- Surgery, anesthesia, 339–350
- Suzuki coupling, 54
- Swern conditions, 177
- Swiss-2DPAGE, 271
- SXR, 64, 84
- SYBL, 48, 281
- Synagis, 30
- Synergism, 18, 60–63, 79
- Synopsis Metabolism Database, 39
- Synsorb, 400
- Syntex, 206
- Synthélabo, 208
- Synthesizers, automated, 141, 143–144
- Synthetic chemistry, 18, 36, 71, 128
- Synthetic chemists, functions of, 129
- Synthetic organic chemistry, 82
- Synthetic organic chemists, functions of, 23
- Synthetic polymers, 384
- Synthetic stereophores, 73
- Systematic studies, drug metabolism, 278
- Systems biology perspectives, 237
- Tag affinity, 252
- Tagamet:
 characterized, 295, 309
 development of clinical candidate drug, 305–309
 historical background, 295–298
 search for H₂-receptor histamine agonists, 298–305
- Tagging reagent, 188
- Taisho Pharmaceuticals (Japan), erythromycin studies, 5
- Takeda, 201–202
- Tamoxifen, 409
- Tandem affinity purification (TAP), 245–246
- Tandem mass spectrometry (MS/MS), 241–242, 255, 257
- Target(s):
 identification, *see* Target identification
 site, types of, 23–24
 specificity, 261
 x-ray diffraction, 25

- Target identification:
 significance of, 1–2, 252
 validation of, 234, 256–259, 266
- Taste, in drug development process, 109
- Taxanes, 43, 413
- Taxoids, 178
- Taxol, 412
- T cells:
 bioengineered, 372
 CD4+, 353
- Tea bags, 131
- Tecan, 24
- Tektronic, 48, 281
- Telmisartan, 201
- Temocapril, 127
- Terazosin, 13–15
- Terfenadine, 205
- Tertiary:
 amines, 72, 388
 structure, defined, 243
- Testing process, overview of, 2–3. *See also specific research studies*
- Tetracycline, 228
- Tetrafluorophthalic anhydride, 185
- Tetrahydrocannabinol (THC), 220
- Tetrahydrofolate, 105
- Tetrahydrofuran (THF), 13, 182
- Tetrazolyl amide, 172
- Teva Pharmaceuticals, 10
- Thalidomide, 222
- Therapeutic activity, 265
- Thiadiazoles, 127, 225
- Thiazinobenzodiazepines, 324–332
- Thiazole, 310
- Thiazolidine-2,4-diones, 200
- Thiocarbonyl, 303
- Thiols, 107, 185, 411
- Thiorexa, 178
- Thiosulfate, 186, 411
- Thiourea, 220, 303, 307–308, 412
 6–31G*, 20, 51
 6–32G*, 282
- Threading, 247
- 3D chemical structures, 47, 49–50, 57, 81
- Three-dimensional descriptors, 138
- 3D quantitative SAR (3D-QSAR), 20, 56
- 384-well:
 arrays, 262
 microplates, 20–21, 260
- Three-phase reaction, 186
- Threonine, 32
- Thrombin receptors agonists, 315
- Thrombocytopenia, 30, 413
- Thymidine, 408
- Thymidylate synthase, 105
- Thymine, 105–106
- Thyroid disorders, 221
- Tiered structures, 55–57
- Tiers, in chemical structure databases, 284–285
- Tiludronate disodium, 209
- Time-of-flight (TOF) separation, 241
- Tinospora*:
 bakis, 416
 cordifolia, 408, 415, 417, 419
- Tipranavir, 226
- Tissue factor VIIa complex, 184
- Tissue plasminogen activators (tPAs), 29
- Tissue-specific delivery, 263
- Tocopherols, 409
- Tolcapone, 219
- Tolvamer, 399
- Tolvaptan, 317
- TOPAMAX topiramate, 314
- Topiramate, 314
- Topographical mapping studies, 28, 31
- Topoisomerase, characterized, 183
- Topoisomerase I⁷⁷, 43
- Topoisomerase I/Topoisomerase II, 371, 413–414
- Topotecan, 43–44
- Tosylated salts, 174, 328
- Tox Express/Gene Express database, 66
- Toxicity:
 assessments, 262
 avoidance strategies, 65–67
 cisplatin-induced, 412
 profile, 262
 significance of, 18, 59–60, 109, 383–384
 studies, 223, 228, 264
 suitable lead substance, 107–108
- Toxic markers, 25
- Toxicology:
 databases, 66
 implications of, 235
- Toxicophores, 21, 37, 65, 107
- Toxins, polymeric sequestration, 397–400
- TOXSYS (SciVision), 66
- Traditional Chinese medicine, 406
- Transcription factors, 239
- Trandolapril, 127
- Tranquilizers, 215
- Transcriptional regulatory networks, 257
- Transcription control, 245
- Trans*-1,4-diaminocyclohexane, 176
- Transgenic species, 28
- Transplantation:
 blood/cell marrow, 30
 rejection, 30
- Transporter system, 71
- Transportophores:
 characterized, 21, 42–43
 relationships, 51
- Trastuzumab, 265
- Triarylphosphine, 188, 190
- Triazine-based compounds, 173

- 1,2,4-Triazolo[4,3-*b*]pyridazines, 170
 3,4,5-Trichloropyridazine, 170
 Tricyclic psychotropics, 222
 Trifluoroacetamide, 190
 2,2,2-Trifluoroethyl group, 325
 Trifluoromethanesulfonyl (Tf), 325
 Triglyceride levels, 202
 Trigonal bipyramid (TBP) transition state (TS), 75, 77
 Triphenylphosphonium ylides, 175
 Tripos Assoc., 48, 281
 Tris(perfluorohexylethyl)silyl group, 190
 2,4,6-Trisubstituted quinazolines, 179
 Troglitazone, 200, 202
²¹Trp, 78
 Tumor(s):
 cells, 151, 370
 -destructive therapy, 370, 408
 metabolism, 376
 metastases, 152, 181, 372
 vascularization, 373
 xenografts, 371
 Tumor necrosis factor (TNF), 408, 416–417
 Tumor necrosis factor- $\forall$ (TNF- $\forall$), 369
 Turner's syndrome, 29
 3–21G*, 20, 51, 282
 2D chemical structures, 47, 54–55, 57
 Two-dimensional descriptors, 138
 Two-dimensional differential in-gel electrophoresis (2D-DIGE), 257
 Two-dimensional polyacrylamide gel electrophoresis (2D-PAGE), 240–241, 253, 255, 257, 264–265
 Tyrosine/tyrosine kinases, 27, 361

 Ubiquitination, 243
 UCSC Genome Browser, 269
 Ugi reaction, 177–178
 UK-92,480, 217
 Ulcers/ulceration, 29, 220, 416–417
 UL-409, 416–417
 Ultiva, 340
 Ultrahigh-throughput screening (UHTS), 21, 79, 355
 Ultraviolet (UV):
 absorption, 242
 detectors, 145
 Underexpression, 259
 U.S. Environmental Protection Agency (EPA),
 High-Volume Chemical (HPV) Screening
 Information Data Sets (SIDS), 66
 U.S. Food and Drug Administration (FDA):
 approval, 254, 265, 362
 guidelines, 359
 labeling, 202
 regulation by, 25, 235–236
 stereoisomers, 70–71
 toxicity, 66

 U.S. Patent and Trademark Office, 9
 Unsaturated esters, 187
 Upjohn, 226
 Urea:
 isostere, 304
 production of, 190
 Uricosuric agents, 221–222
 Uridinediphosphoglucose dehydrogenase, 417
 Urinary tract protectants, 412
 Urine, 113, 115
 Urothelial toxicity, 412
 Urotoxicity, 412, 415
 Urticaria, 298

 Vaccination/vaccines, 249, 368, 370
 Validity of data, 234, 254, 256–259, 266
 Valsartan, 201, 215–216
 Vancomycin:
 characterized, 398
 resistant enterococci, 400
 Vascular-endothelial growth factor (VEGF) receptor, 373
 Vasoconstriction, 316
 Vasopressin receptor antagonists:
 azepinoindoles, 319, 321–322
 background of, 313–315
 bridged bicyclic derivatives, 322–324
 characterized, 315–317
 oxazinobenzodiazepines, 324–332
 project genesis, 315
 pyrazinobenzodiazepines, 324–332
 study design, 317–319, 332–333
 thiazinobenzodiazepines, 324–332
 Veber, Daniel, 113
 Veber rule, 113
 Vespeside, 412
 Vezluma, 30
 Viagra, 217
 Vibrational frequencies, molecular conformation, 51
Vibrio cholera, 397
 Vicinal dibromides, 187
 Vinyl amine polymers, 394
 Virtual compound libraries/virtual library, 79, 84, 137, 284
 Virtual screening, 37, 260
 Virus(es):
 evolution of, 40
 infectivity, 181
 inhibition of, 397
 replication, 181, 361–362
 Viscinol diols, 186
Viscum album, 408
 Vitamin E, 414
 Vitravene, 30
 VPA-985, 317, 325, 327
 V₂ selectivity, 326–327, 329, 332

- Wandering behavior, 370
- Wash cycles, 143
- Wasting, AIDS-related, 29
- Watanabe, Yoshiaki, Dr., 5
- Water:
 - retention, 316
 - solubility, 109, 111–115, 228
- WebGene, 269
- WebLogo, 269
- Web sites, as information resource, 19, 24
- Weighting decision criteria, 67–70, 143
- Weight loss, 220
- WelChol, 396
- Wellcome, 204
- Western immunoblot analysis, 264
- Winn, Marty, Dr., 13
- Withaferin A, 418–419
- Withaferins, 415
- Withaferin somnifera*, 408–409, 417–418
- Withanolides, 415, 418
- Wittig cyclization/reaction, 175, 185, 187
- Wolff-Parkinson-White syndrome, 221
- Workflow, combinatorial library management, 146–147
- Workstations, automation, 149
- World Health Organization, 353
- WR2721, 412
- Wyeth Pharmaceuticals, 315
- Xanthine, 172
- Xenobiotic(s):
 - characterized, 21, 35, 278
 - directing distribution, 58–59
 - elimination of, 65
 - metabolism database, 286
- Xenograft models, 372
- X-ray(s):
 - ACE inhibition study, 122
 - combinatorial library design, 140
 - crystallographic studies, 21, 176, 246, 260
 - diffraction, 18, 23, 25–26, 33, 35, 38, 76, 79, 135, 328
 - drug metabolism studies, 282–284
 - inhibitor functions studies, 105
 - molecular conformation assessment, 47, 49–51, 53, 57
- Xylene, 357
- XYZ synthesizers, 142–144
- Yamanouchi, 209
- Yeast/two-hybrid (Y2H) studies, 245, 368
- y ions, 241–242
- YM-087, 317
- Zalcitabine, 361
- Zantac, 310
- Zenapax, 30
- Zhu, Heng, 250
- Zidovudine, 353–354, 361
- Zinc, 120, 391
- Zinc-metalloproteases, 120
- Zoledronate disodium, 209
- Zolmitriptan, 204
- Zopiclone, 215
- Zymark, 24